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1 .  I N T R O D U C T I O N  
1.1 Adult neurogenesis in the mammalian brain 
Adult neurogenesis in mammals is defined as the life-long addition of new neurons to the brain 
(Altman and Das, 1965). These newborn neurons originate from neural stem cells (NSC) that 
reside in two specific areas of the mammalian brain: the subgranular zone (SGZ) within the 
hippocampus (Toda and Gage, 2018) and the subventricular zone (SVZ) lining the ventricular 
walls (Figure 1)(Lim and Alvarez-Buylla, 2016). Since the identification of NSCs in the adult 
mammalian brain (Reynolds and Weiss, 1992), a plethora of studies have focused on their 
origin, properties, differentiation potential and ultimately the biological function of the newborn 
neurons that integrate into the existing circuitry and can add an additional layer of plasticity to 
the brain on demand (reviewed in (Gage and Temple, 2013; Bond et al., 2015)).  
 
Figure 1: Neurogenic zones in the adult mammalian brain 
Drawing of a sagittal section through an adult mouse brain (A) and a coronal section through an adult 
human brain (B) with the two neurogenic zones (subventricular zone and subgranular zone) highlighted 
in green. Inspired by and modified from (Magnusson and Frisen, 2016). 
 
Adult neurogenesis in mice 
In the well-studied model organism mouse, the presence of NSCs and adult neurogenesis is 
undebated (Figure 1A). However, it is known that the numbers of NSCs decline with ageing 
and two studies published in 2011 came to different conclusions as to whether the stem cell 
pool is exhausted at some point in life or not (Bonaguidi et al., 2011; Encinas et al., 2011). 
Neurogenic zones in the adult mammalian brain
subventricular
zone (SVZ)
subgranular
zone (SGZ)
mouse human
A B
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While Bonaguidi et al. observed both symmetric and asymmetric divisions and long-time self-
renewal of NSCs in the SGZ, Encinas et al. did not see symmetric divisions at all in NSCs in 
the SGZ. Furthermore, they observed an exhaustion of the stem cell pool because once NSCs 
were exiting quiescence, there was no coming back and they would eventually turn into 
astrocytes after several rounds of asymmetric neurogenic divisions. Both studies used Nestin+ 
cells to identify NSCs in vivo, but Bonaguidi et al. used a Cre-lineage tracing approach for 
clonal analysis, whereas Encinas et al. investigated mainly Nestin-GFP transgenic animals on 
a NSC population level. 
Another lineage-tracing study in the SGZ demonstrated the heterogeneity of the NSC pool by 
using either Nestin- or GLAST-driver lines that showed differences in terms of self-renewal 
capacity and responsiveness to neurogenic stimuli (DeCarolis et al., 2013). Interestingly, the 
Nestin-population showed a plateau and did not respond to neurogenic stimuli, whereas the 
GLAST-population continuously increased over time and also increased its neurogenic output 
upon stimulation. The heterogeneity of NSCs was further corroborated by in vivo longitudinal 
imaging of lineage-traced Ascl1+ NSCs (Pilz et al., 2018). This population underwent several 
rounds of symmetric divisions before changing to asymmetric neurogenic divisions and 
eventually being consumed. The authors did not observe a shuttling between quiescent and 
activated NSCs but acknowledged that another population of NSCs might be able to do so. 
In the SVZ, it has been found that the age-related decline in neurogenesis happens 
downstream of the NSC population and that the proportion of actively dividing NSCs even 
increases (Shook et al., 2012). SVZ NSCs mainly undergo symmetric divisions (either for 
expansion or differentiation) based on lineage-tracing experiments which leads to the 
maintenance of neurogenesis over life (Obernier et al., 2018). Notably, recent single cell 
transcriptomics of the SVZ showed a decrease of NSCs with ageing but a concomitant 
compensating increase in quiescent NSCs that had similar proliferation and differentiation 
capacities as “young” NSCs once activated (Kalamakis et al., 2019). 
 
Adult neurogenesis in humans 
In humans (Figure 1B), the first evidence for adult neurogenesis was provided by a study by 
Eriksson and colleagues where they injected the thymidine analogue BrdU into cancer patients 
for diagnostic purposes. BrdU is incorporated into the DNA of proliferating cells and post-
mortem, they found BrdU+ cells in the hippocampus of those patients (Eriksson et al., 1998). 
The existence of adult NSCs was indicated after the isolation and in vitro propagation of human 
neural precursor cells of post-mortem tissue that had similar properties as the already known 
fetal NSCs (Palmer et al., 2001). Not only the hippocampus, but also the SVZ in humans was 
shown to harbour neurogenic potential via the same BrdU approach as before (Curtis et al., 
2007). Successive studies focusing on known markers for immature neurons such as 
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doublecortin (DCX) implicating neurogenesis corroborated the previous findings (Liu et al., 
2008; Knoth et al., 2010). Another interesting approach was the analysis of nuclear bomb test-
derived 14C incorporation and based on that the calculation of the age of a cell. First, this 
technique showed that there were close to no new neurons in the olfactory bulb (where 
newborn neurons derived from the SVZ end up in other mammals typically (Bergmann et al., 
2012)) but later on could provide further confirmation of adult neurogenesis both in the 
hippocampus (Spalding et al., 2013) and in the SVZ (Ernst et al., 2014). Remarkably, the latter 
study also identified that newborn neurons from the SVZ ended up in the striatum in contrast 
to other mammalian species.  
However, all of the different techniques that had been used to identify NSCs or adult 
neurogenesis have their caveats. The BrdU studies used tissue from cancer patients and 
consequently, the detected proliferating cells in the brain could possibly originate either from 
metastatic tumour cells or from non-proliferative DNA damage-induced BrdU incorporation. 
Relying solely on markers that are known to prove neurogenesis in animal models is also not 
considered convincing since it is possible that other cell types such as glia express low levels 
of DCX. Furthermore, an increased incorporation of 14C could also originate from DNA 
methylation or DNA repair. 
Further research was also investigating whether adult neurogenesis in humans changes with 
ageing. One of the 14C studies claimed that there was only a small decline in the hippocampus 
(Spalding et al., 2013) whereas subsequent marker-based data suggested either a rapid or at 
least a pronounced decline with ageing (Dennis et al., 2016; Mathews et al., 2017). This debate 
has spiked even more recently with two studies published in 2018 about adult hippocampal 
neurogenesis, both based on marker stainings of post-mortem brains but coming to different 
conclusions (Boldrini et al., 2018; Sorrells et al., 2018). 
While Boldrini et al. claimed that the number of progenitors and newborn neurons does not 
change over life, Sorrells et al. found that neurogenesis in humans drops sharply after one 
year of life and that newborn neurons were below the detectable threshold in adulthood, 
corroborated also by similar findings in monkeys. In a follow-up commentary about those two 
publications, Kempermann et al. highlighted important differences in the post-mortem tissue 
processing of those two studies which can drastically influence the result (Bao and Swaab, 
2018; Kempermann et al., 2018). Another interesting perspective came from Laura Andreae’s 
commentary (Andreae, 2018), raising the point that the human brains analysed in the Boldrini 
study ranged from 14 to 79 years which is a time span where neurogenesis did not change 
anymore according to Sorrells et al. Thus, the reported numbers of adult-born neurons in those 
two studies might be actually more similar than the two groups claimed. Andreae concludes 
with the question “how rare is rare” and whether a few thousand newborn neurons in the entire 
hippocampus could actually make a difference. 
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More recent marker-based studies have yet again reported the detection of thousands of 
newborn neurons also in old human brains after optimising the protocol for post-mortem 
processing of the brains (Moreno-Jimenez et al., 2019; Tobin et al., 2019), leaving the field still 
wide open for future discoveries and debates. Although all of the used techniques have their 
caveats as outlined before, all the data combined rather supports at least a low level of adult 
neurogenesis in humans both in the striatum and in the hippocampus. The latter could explain 
the high cognitive functions of humans that the hippocampus contributes to and the former is 
raising hopes for providing a resource of neuronal regeneration (see also chapter 1.3). 
 
1.1.1 The NSC lineage 
Due to the restricted abilities to investigate NSCs in humans in vivo, the majority of 
characterisations of the NSC lineage has been conducted in the mouse. NSCs, like other stem 
cells, can shuttle back and forth between a quiescent and an active cycling state thereby 
undergoing different types of cell divisions. They can either divide symmetrically to create two 
new NSCs (expansion) or two differentiating progenitors (consumption), or they can 
alternatively divide asymmetrically to generate one NSC and one differentiating progenitor 
(self-renewal, reviewed in (Bond et al., 2015)), although there are several studies indicating 
that NSCs almost exclusively undergo symmetric divisions and asymmetric divisions are 
observed very rarely in both niches (Bonaguidi et al., 2011; Encinas et al., 2011; Calzolari et 
al., 2015; Obernier et al., 2018; Pilz et al., 2018). 
In both SGZ and SVZ, NSCs can be histologically identified by their marker expressions of 
Sox2, GFAP and Nestin and they can differentiate either into GFAP- and S100b-expressing 
astrocytes or towards neural progenitors (Figure 2). These Ascl1+ and Neurog2+ progenitors 
have a limited self-renewal capacity and give rise to DCX-expressing neuroblasts. 
Subsequently, the neuroblasts differentiate to newborn neurons that eventually mature into 
NeuN+ adult neurons which further specify into neuronal subtypes (Codega et al., 2014; 
Goncalves et al., 2016; Toda and Gage, 2018). 
Neuroblasts in the SGZ remain within the dentate gyrus and locally differentiate into neurons, 
whereas in the SVZ, the neuroblasts migrate along the rostral migratory stream (RMS) to the 
olfactory bulbs (OBs) where they differentiate into neurons. All these decisions are not only 
driven by cell-intrinsic factors but also by extrinsic signals, mainly conveyed by the NSC niche 
which is comprised of the surrounding cells (Ottone et al., 2014; Licht and Keshet, 2015). 
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Figure 2: Neural stem cells and their progeny 
Scheme of NSCs in their quiescent (grey) or active (blue) state and their progeny after differentiation: 
astrocytes (yellow), neural progenitors (blue-green) with limited self-renewal capacity, neuroblasts (blue-
green) and newborn neurons (green). Below: important marker expression of each cell type is shown. 
 
1.1.2 The NSC niche 
The subventricular zone 
The SVZ is a 3-4 cell layers thick zone separated from the ventricular cerebrospinal fluid (CSF) 
by the ependymal cells (Figure 3A). Both ependymal cells and NSCs are in contact with the 
CSF with their cilia while NSCs also have a long basal process contacting blood vessels 
(Mirzadeh et al., 2008). Many growth factors such as FGF-2, EGF and BDNF and signalling 
pathways like Hedgehog, BMP, Wnt and Notch have been shown to play a pivotal role in 
regulation and maintenance of the niche (Lim and Alvarez-Buylla, 2016). Neural progenitors 
and neuroblasts are surrounding the NSCs while neuroblasts migrate via the RMS towards the 
OB and differentiate into g-aminobutyric acid (GABA)ergic interneurons (Gheusi et al., 2000; 
Ponti et al., 2013). Interestingly, there are also reports that the SVZ NSCs can differentiate 
towards the astro- and oligodendroglial lineage but this happens very rarely under 
physiological conditions (Menn et al., 2006). 
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Figure 3: The neural stem cell niche in the SVZ 
(A) Drawing of the NSC niche in the SVZ. Ependymal cells (brown) are surrounding NSCs (blue) and 
neural progenitors (NP, green). NSCs are in contact with the ventricular surface and blood vessels. 
Underneath are neuroblasts (red). Adapted from (Mirzadeh et al., 2008). (B) Drawing of the NSC niche 
in the SGZ. NSCs (blue) are in contact with blood vessels (red) and surrounded by their progeny 
(progenitors in grey and green, neuroblasts in brown, newborn neurons in green, adult neurons and 
astrocytes in yellow, interneurons in red). Modified from (Lin and Iacovitti, 2015). 
 
The subgranular zone 
The SGZ is located within the dentate gyrus of the hippocampus (Figure 3B). The NSCs are 
in close contact with blood vessels underneath the granule cell layer and have a radial glia-
like morphology. Like in the SVZ, many growth factors and signalling pathways have been 
shown to influence the behaviour of the NSCs such as BDNF, FGF-2, VEGF, Notch, 
Hedgehog, BMP and Wnt signalling (Goncalves et al., 2016). After several rounds of 
proliferation and differentiation, the resulting neuroblasts only migrate very short distances into 
the granule cell layer where they differentiate into newborn neurons. After 6-8 weeks of 
maturation which is crucial for the survival and integration of the newborn neurons, they 
eventually become fully functional and indistinguishable from the other granule neurons (Toni 
and Schinder, 2015). 
 
1.1.3 The role of neurogenesis in the adult brain 
Newborn neurons from the SVZ 
Since the progeny of SVZ NSCs contribute to neurons in the OB, many approaches including 
manipulation of neurogenesis or survival of the newborn neurons have been used to 
investigate the role of SVZ neurogenesis in olfaction of mice.  
Knock-out of neural cell adhesion molecule (NCAM) in mice showed deficits in migration of 
neuroblasts leading to a 40 % size reduction of the OB and impairments in odour discrimination 
NSC
NP
NB
ependymal cells
SVZ
A Subventricular zone (SVZ)
neural stem
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astrocyte
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interneuron
mature
neuron
type 2a
progenitor
neuroblast
newborn
neuron
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but not odour detection thresholds or short-term memory (Gheusi et al., 2000). Ablation of 
neurogenesis by NSC-specific overexpression of diphtheria toxin fragment A, however, did not 
influence odour-associated memory formation nor odour long-term memory although the 
authors mentioned that more difficult tasks might be neurogenesis-dependent (Imayoshi et al., 
2008). Injection of the antimitotic agent cytarabine (araC) into the ventricle for a month stopped 
the addition of newborn neurons to the OB during this period and short-term olfactory memory 
was impaired but no difference in spontaneous odour discrimination or long-term odour-
associative memory tasks were observed (Breton-Provencher et al., 2009). Specific irradiation 
of the SVZ decreased neurogenesis for several months without affecting odour discrimination 
and short-term odour memory, but causing impairments on long-term memory (Lazarini et al., 
2009). 
Interestingly, when instead enhancing neurogenesis by preventing programmed cell death via 
local application of caspase inhibitor in the OB, the number of newborn neurons increased but 
olfactory reaction time was worse without changing olfactory learning or memory (Mouret et 
al., 2009). Similarly, knock-out of the pro-apoptotic gene Bax did not change SVZ proliferation 
or OB size but caused some neuroblasts to be stuck in the SVZ and to locally differentiate to 
neurons. Moreover, no behavioural changes were observed in that study (Kim et al., 2007). In 
contrast, increased differentiation and survival of newborn neurons by MAP kinase ERK5 
activation in SVZ NSCs improved short-term memory (Wang et al., 2015a). BDNF has also 
been shown to increase both proliferation and neurogenesis in the SVZ although no 
behavioural tests have been conducted (Zigova et al., 1998; Henry et al., 2007). Similarly, 
microRNA-210 overexpression in the SVZ increased proliferation again lacking behavioural 
analysis (Zeng et al., 2014). Notably, when specifically activating adult-born neurons in the OB 
using optogenetics, mice improved in difficult odour discrimination (Alonso et al., 2012). 
Despite the evidence that SVZ neurogenesis is playing a role in olfaction, these studies could 
still not reveal to what extent an increase in NSCs can influence the behavioural performance. 
 
Newborn neurons from the SGZ 
The hippocampus is important for learning and memory and the role of adult-born neurons is 
thought to be dependent on their age spanning from two to four and six weeks until they are 
considered completely integrated into the circuitry, fully mature and undistinguishable from 
other neurons (Ge et al., 2007; Toni et al., 2007). Different methods have been used to 
investigate the contribution of adult neurogenesis to the function of the hippocampus, amongst 
them several that manipulated neurogenesis itself at different levels.  
For example, dividing NSCs were specifically killed using the herpes simplex virus thymidine 
kinase leading to reduced neurogenesis by as much as 98 % accompanied by behavioural 
deficits in spatial and/or contextual memory (Garcia et al., 2004; Saxe et al., 2006; Deng et al., 
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2009). When DCX+ cells were targeted, expectedly the number of newborn neurons was 
reduced resulting in a worse outcome in behaviour after stroke (Jin et al., 2010). Other 
strategies like NSC-specific overexpression of toxins such as the pro apoptotic protein Bax or 
diphtheria toxin fragment A both yielded spatial and/or contextual memory impairments (Dupret 
et al., 2008; Imayoshi et al., 2008). 
On the other hand, efforts have been made to increase the existing levels of neurogenesis, 
one of the first being animals living in an enriched environment (Kempermann et al., 1997) 
leading to more proliferation and cell numbers accompanied by better performance in water 
maze learning. Furthermore, physical exercise (mice in a running wheel) has been shown to 
be sufficient to induce increased proliferation and neurogenesis in the SGZ (van Praag et al., 
1999). Additionally, dietary restriction increased the number of proliferating cells due to a 
reduction of cell death of newborn neurons (Lee et al., 2000). These more holistic approaches 
affecting many aspects of the animal led to the discovery of more targeted ways of increasing 
neurogenesis such as growth factors. 
Systemic administration of IGF-I promoted proliferation and neurogenesis in the SGZ (Aberg 
et al., 2000) whereas injection of NGF directly into the brain promoted survival of newborn 
neurons (Frielingsdorf et al., 2007) and increased proliferation in the SGZ and the animals’ 
performance in recognition memory (Birch and Kelly, 2013). Similar effects were observed with 
BDNF (Pinnock and Herbert, 2008), CNTF (Chohan et al., 2011) and the adipose-derived 
hormone leptin (Garza et al., 2008). Besides injection of growth factors, also their 
overexpression has led to increased neurogenesis. When overexpressing VEGF in the entire 
brain, its total size was increased as were the proliferation rates in both SGZ and SVZ and 
animals showed reduced fear and aggression (Udo et al., 2008). 
Furthermore, transgenic overexpression of the anti-apoptotic protein Bcl-2 in the dentate gyrus 
increased the number of DCX+ cells older than 7 days without affecting early progenitors or 
proliferation (Kuhn et al., 2005). Conversely, knock-out of phosphodiesterase-4D increased 
proliferation in the SGZ via the cyclic adenosine monophosphate (cAMP) pathway improving 
reference memory of mice (Li et al., 2011). 
All these examples of different manipulations have revealed a complex network of factors 
influencing neurogenesis in the SGZ, some of them even leading to behavioural changes. This 
underlines the importance of adult neurogenesis and also its responsiveness to external stimuli 
(e.g. physical exercise) for the hippocampal role in learning and memory – yet, more 
mechanistic studies are needed to further investigate its function. 
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1.1.4 Specific NSC pool expansion by Cdk4/Ccnd1 overexpression 
Since all the previously mentioned studies were not able to elucidate the explicit contribution 
of neurogenesis to brain function due to the lack of targeted approaches, our lab had 
established a method to specifically expand the NSC pool. Lange et al. first demonstrated that 
overexpression of Cdk4/Ccnd1 (4D) in NSCs in the developing mouse cortex shortens their 
G1 thus leading to an increased proliferation (Lange et al., 2009). When using this technique 
in a transgenic mouse model instead of local electroporation as before, a 4D-triggered NSC 
expansion right before the peak of embryonic neurogenesis led to adult mice with bigger brains 
(Nonaka-Kinoshita et al., 2013). Moreover, this effect was not restricted to embryonic 
development as 4D overexpression in the adult mouse brain using a lentiviral system was 
triggering increased proliferation in the hippocampal SGZ (Artegiani et al., 2011) and also in 
the SVZ using a transgenic mouse (Figure 4 A&B) (Bragado Alonso et al., 2019). In both cases, 
this increased stem cell pool gave rise to more newborn neurons after switching off 4D 
overexpression (Figure 4C) and for OB neurons, it was demonstrated that this increased 
number of neurons enabled mice to differentiate better between very similar odours (Bragado 
Alonso et al., 2019). This was the first direct manipulation of SVZ NSCs that described an 
improvement of the olfactory performance when facing a very difficult task. Hence, 4D 
overexpression does not only provide a useful approach to study the role of neurogenesis but 
could also enable exploiting the endogenous plasticity potential of the brain in the context of 
diseases. 
Many studies have reported a response of the SVZ neurogenic niche to different brain 
damages (reviewed by (Nemirovich-Danchenko and Khodanovich, 2019)). SVZ neural 
progenitors have been shown to migrate towards the site of injury in addition to their normal 
migratory path along the RMS. This fact has been raising the question whether or not an 
increased level of neurogenesis might be beneficial for recovery from those adverse events 
and will be discussed in a separate section (see chapter 1.3). 
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Figure 4: Effect of 4D overexpression on NSCs and their progeny 
Scheme of NSCs (blue), neural progenitors (blue-green), neuroblasts (blue-green) and newborn 
neurons (green) under physiological conditions (A), during 4D overexpression in NSCSs (B) and after 
4D overexpression (C). 
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1.2 Mouse models of neurodegenerative diseases 
Neurodegenerative diseases are characterized by the loss of neurons and are mostly sporadic 
with an increasing risk with age, although there are monogenetic early-onset forms in some 
instances. With an increasingly ageing population, it is more and more important to find 
effective treatments which have been elusive in many cases until now (Logroscino and Tortelli, 
2015). Thus, preclinical research in animal models is highly needed and mice depict a useful 
model organism because of the advanced available genetic tools. In the following, the most 
common neurodegenerative diseases, the respective potential relevance of the two 
neurogenic niches and their mouse models will be presented. 
 
1.2.1 Alzheimer’s Disease 
Alzheimer’s Disease (AD) is characterised by an early cognitive decline including memory 
deficits and impairments in executive functions. Histologically, AD is defined by three 
hallmarks: Ab plaques (characteristic for AD only), tau tangles (also in other neurodegenerative 
diseases) and hippocampal and cortical neurodegeneration. It has been found that mutations 
in APP, PSEN1 and PSEN2 are main drivers for early-onset AD, whereas APOEe4 is a risk 
factor for late-onset (Carmona et al., 2018). 
Since AD affects also the hippocampus, investigating a potentially beneficial contribution of 
SGZ neurogenesis to AD in different mouse models is of high interest. These models are either 
focused on Ab plaques, tau tangles or both and thus reproduce more or less histological and 
behavioural aspects of neurodegeneration and cognitive impairments. The vast majority 
consists of genetically modified models (knock-in or transgenic with human mutations of 
affected proteins), but other models like seeding of Ab by injection also exist. Yet, AD is a very 
complex neurodegenerative disease to model because of the heterogeneity of the disease 
itself and of available models (Jankowsky and Zheng, 2017). 
 
1.2.2 Parkinson’s Disease 
Parkinson’s Disease patients typically show motor symptoms like resting tremor and rigidity. It 
is caused by a progressive loss of dopamine (DA) neurons in the substantia nigra pars 
compacta due to misfolded a-synuclein in Lewy bodies and neurites (Savitt et al., 2006). 
Despite the majority of cases being sporadic, genetic mutations in several genes have been 
linked to the disease such as in a-synuclein or LRRK2, parkin and PINK1 (Klein and 
Westenberger, 2012). 
Due to the close proximity of the striatal DA neurons to the SVZ, the therapeutic potential of 
SVZ NSCs in PD models is of high interest. The most commonly used animal models are drug 
induced by either 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6-hydroxydopamine 
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(6-OHDA) both specifically killing dopaminergic neurons in the striatum when administrated 
systemically leading to variable motor deficits (Vingill et al., 2018). Alternatively, genetic 
models with mutations in PD affected genes have been used such as DA neuron-specific 
overexpression of mutant a-synuclein (Lin et al., 2012) or LRRK2 (Xiong et al., 2018), or 
knockout of parkin (Shin et al., 2011) and knockdown of PINK1 (Lee et al., 2017). 
However, the drug induced models have so far failed to identify potential therapeutical 
approaches (Athauda and Foltynie, 2016) and genetic models only highlight a certain aspect 
of the disease that only affect a minority of patients.  
 
1.2.3 Huntington’s Disease 
The autosomal-dominant Huntington’s Disease (HD) is characterised by development of 
chorea and psychiatric and cognitive disabilities that typically lead to death of the patients 
within 10-20 years after onset (Glorioso et al., 2015). A poly-glutamine extension in the 
huntingtin protein is causing the disease resulting in misfolding and cytoplasmic aggregations 
that induce the death of medium spiny neurons in the striatum and degeneration of the cortex 
and hippocampus (Cisbani and Cicchetti, 2012). 
Similar to AD and PD, HD affects areas either containing a neurogenic niche (hippocampus) 
or in close proximity to it (striatum to SVZ) thus raising the question whether increased 
neurogenesis could be beneficial for this disease. A variety of genetic mouse models have 
been created introducing the poly-glutamine repeats, ranging from transgenic N-terminal 
huntingtin fragments to full length and knock-in models (Farshim and Bates, 2018). 
Importantly, humans usually have less repeats with a more severe phenotype compared to the 
mouse models, also because the aim of the models is usually to speed up the disease process. 
 
1.2.4 Amyotrophic Lateral Sclerosis 
In amyotrophic lateral sclerosis (ALS), upper and lower motor neurons are lost, ultimately 
leading to respiratory failure and death typically within 1-5 years (Andersen and Al-Chalabi, 
2011). Histologically, TDP-43 inclusions have been identified as pathological hallmark 
(Neumann et al., 2006). ALS is sporadic most of the times, but mutations in SOD1 and other 
genes (Taylor et al., 2016) among them the C9orf72 gene (DeJesus-Hernandez et al., 2011; 
Renton et al., 2011) have been linked to the disease. 
ALS does not affect specific brain areas but the migratory potential of SVZ-derived neuroblasts 
could still be beneficial. There are three main genetic mouse models being used. 
Overexpression of SOD1 mutations (Philips and Rothstein, 2015) recapitulate many aspects 
of the human disease, both on the cellular and behavioural level although there is no TDP-43 
pathology. On the other hand, TDP-43 overexpression models show varying symptoms based 
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on how the overexpression is achieved and what form of TDP-43 is used (Swarup et al., 2011). 
More recently developed C9orf72-based models have also been reported to present 
neurodegeneration and cognitive impairments (Liu et al., 2016). 
 
1.2.5 Multiple Sclerosis 
Multiple sclerosis (MS) is different compared to the previously introduced neurodegenerative 
diseases because of the involvement of the immune system. For unknown reasons, the 
patient’s immune cells in this disease target the own oligodendrocytes causing demyelination 
and axonal damage in the brain leading to motor and cognitive dysfunctions (Peruga et al., 
2011). 
It has been shown that SVZ NSCs can also contribute to the oligodendroglial lineage 
highlighting the potential versatility of endogenous NSCs (Menn et al., 2006). There are three 
established mouse models described in the literature: the experimental autoimmune 
encephalomyelitis (EAE), Theiler’s murine encephalomyelitis virus (TMEV) infection-induced 
demyelination and toxin-induced demyelination. 
EAE is most commonly used and is achieved by injection of a myelin peptide, the immune-
system activating Freund’s adjuvant and pertussis toxin to disrupt the blood brain barrier. 
These injections prime the immune cells against oligodendrocytes, recapitulating all important 
features of MS:  inflammation, demyelination, axonal loss and gliosis plus behavioural deficits 
both as paralysis of body parts and motor coordinative impairments (Miller and Karpus, 2007; 
van den Berg et al., 2016). 
TMEV infection causes chronic progressive inflammatory demyelinating disease in mice and 
depending on the TMEV type used, the severity and onset of symptoms are variable, but in 
either case, the obtained phenotype includes paralysis, locomotor impairments and also 
increased sensitivity to thermal pain as observed in MS patients (Lynch et al., 2008; Procaccini 
et al., 2015). 
Finally, for the toxin-induced demyelination, cuprizone is most commonly used which 
specifically kills oligodendrocytes and leads to demyelination. Remyelination occurs when 
stopping the cuprizone treatment and subtle behavioural symptoms can be detected using a 
complex running wheel (Liebetanz and Merkler, 2006) although this model does not involve 
the immune system. 
 
1.2.6 Stroke 
Stroke can be divided into two categories, the ischemic and the haemorrhagic stroke. While 
ischemic stroke is more common in humans (80 % of the cases) and is characterized by a cut-
off in blood supply for a brain area, haemorrhagic stroke occurs less frequently (20 %) and is 
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caused by the rupture of blood vessels (Bamford et al., 1991). The SVZ NSC niche has been 
reported to be responsive upon stroke and migration of neuroblasts to the injury site might be 
beneficial (Marques et al., 2019; Nemirovich-Danchenko and Khodanovich, 2019). There are 
three conceptually different models of ischemic stroke in rodents, the artery occlusion, light-
inducible and chemically inducible stroke. 
 
1.2.6.1 Artery occlusion 
One of the oldest and still most commonly used model of ischemic stroke is occlusion of 
arteries (Koizumi et al., 1986). This can be achieved by different methods like injecting 
preformed blood clots or by inserting a surgical filament (Beech et al., 2001; Gerriets et al., 
2004). In both cases, the middle cerebral artery is targeted for the occlusion (MCAo) which 
can be complemented with occlusion of the common carotid artery (CCAo). In case of the 
surgical filament insertion, this occlusion can be made permanent or transient, allowing 
reperfusion to occur. This stroke model has the advantage of closely resembling the 
pathophysiology of stroke in humans and does not require craniotomy but the mortality rate is 
high because the reported ischemic damage can affect up to half of a hemisphere. Moreover, 
the size and location of the stroke are highly variable and show a variety of impairments in 
different behavioural tests for motor coordination (rotarod, chimney test, pole test) or 
sensorimotor function (corner test, adhesive removal test, staircase test) and memory function 
(passive avoidance and water maze) (Hunter et al., 2000; Bouet et al., 2007; Wen et al., 2017). 
 
1.2.6.2 Light-inducible stroke model 
Another stroke model is light-inducible and called photothrombotic stroke. In this model, the 
photosensitive dye Rose Bengal is injected intraperitoneally (i.p.) to the mouse and distributed 
in the blood system of the entire body within a few minutes. This dye itself does not induce any 
damage, but upon activation by a cold-light source, it causes the formation of oxygen radicals 
that damage the endothelial wall of blood vessels, leading to the activation of thrombocytes 
and of the thrombotic cascade ultimately forming a blood clot (Watson et al., 1985). This 
technique is usually used to induce cortical ischemia because it is minimally invasive. The skin 
has to be cut, but the cold light can be shined directly on top of the skull. For a targeted stroke 
in deeper brain areas, an optic fibre can be used (Kuroiwa et al., 2009). In this case, the 
procedure is not as minimally invasive anymore since a small hole has to be drilled into the 
skull and the optic fibre (~1 mm diameter) has to be inserted into the brain. Several studies 
have reported sensorimotor impairments in both rats and mice after cortical photothrombotic 
stroke (Diederich et al., 2012; Li et al., 2014; Okabe et al., 2017; Alamri et al., 2018). 
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1.2.6.3 Chemically inducible stroke model 
A third model of stroke is taking advantage of the small peptide hormone Endothelin-1 (ET-1). 
It is naturally produced by vascular endothelial cells and used by the body to control 
vasoconstriction of blood vessels (Davenport et al., 2016). For the stroke model, ET-1 is 
combined with the NOS inhibitor L-NAME preventing NOS-induced vasodilatation (Horie et al., 
2008). Both those chemicals can be stereotaxically injected into any desired brain area to 
cause local vasoconstriction and thereby resulting in relatively small but targeted ischemic 
damage. ET-1 has been used to mainly target cortical areas and has shown both in mice and 
rats impairments in sensorimotor, locomotor and anxiety tests (Windle et al., 2006; Tennant 
and Jones, 2009; Roome et al., 2014; Happ et al., 2018).  
 
Taken together, all three stroke models cause ischemic stroke in various brain areas in 
mechanistically different ways but the aim is always to mimic the natural cause of stroke i.e. a 
blood clot cutting off nutrition for certain brain areas. 
While MCAo/CCAo are least invasive in regard to the brain itself and cause the biggest 
damage, they have the major disadvantage of high variability and unspecificity to certain brain 
regions. 
The photothrombotic stroke on the other hand is the least invasive model when targeting 
cortical areas, can be relatively precise when using focused cold-light and causes minor local 
damage. If deeper layer structures shall be targeted the use of an optic fibre increases 
variability of the stroke and is not minimally invasive anymore. 
ET-1 stroke is less invasive for deeper structures as compared to the photothrombotic stroke 
because only a very thin glass capillary is inserted into the brain to inject the chemicals instead 
of a relatively thick optic fibre. Since the capillary is also less flexible than the optic fibre, the 
precision and thus the reproducibility should be higher for ET-1. Moreover, the small ischemic 
damage usually caused by ET-1 can be scaled easier since the volume of injected ET-1 is 
much more precisely controllable as compared to the cold-light of the optic fibre (and also its 
exact orientation within the tissue). 
 
1.3 Neuronal replacement approaches for neurodegenerative diseases 
Ongoing efforts have been made to identify new treatments of the aforementioned 
neurodegenerative diseases. Besides pharmacological therapies to ameliorate the symptoms 
and to ease the burden of each of those diseases, the increasing knowledge about stem cells 
has opened the door to many therapeutic approaches, among them cell transplantations or 
the use of endogenous cells as a regenerative source by in vivo reprogramming or 
manipulation of the NSCs in the neurogenic niches. 
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1.3.1 Cell transplantations  
Initially, cells from fetal midbrains as a mixed source of neurons and NSCs were used and 
provided positive results for both HD (Bachoud-Levi et al., 2000) and PD (Mendez et al., 2005; 
Mendez et al., 2008) patients. Surprisingly, not only motor coordination was improved but cells 
were shown to survive as long as 14 years after transplantation. However, in a double-blinded 
study, the behavioural improvements observed in the previous open-label PD trials could not 
be seen (Olanow et al., 2003). Furthermore, fetal cells do not depict a good resource of cells 
for regenerative therapies due the limited access to fetal material and ethical concerns. 
Remarkably, the isolation and discovery of embryonic stem cells (ESCs) (Thomson et al., 
1998) and induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Takahashi 
et al., 2007) have expanded the toolbox of stem cell research enormously. Differentiation in 
vitro of iPSCs/ESCs to DA neurons, for example, and their subsequent transplantation into PD 
mice has been achieved successfully (Kim et al., 2002; Kriks et al., 2011). Moreover, this 
technique cannot only be used for neuronal replacement, but could also enable correction of 
mutations prior to differentiation of patient iPSCs into the neuronal subtypes needed. This has 
been successfully done for HD (An et al., 2012). Furthermore, instead of differentiating the 
iPSCs to neurons, protocols have also been developed to stop the differentiation process at 
the NSC stage (Thier et al., 2012). These cells have the advantage that they are expandable 
in culture but are already committed to the neural lineage and they were shown to also be 
transplantable. Alternatively, fibroblasts can also be directly converted to NSCs (Lujan et al., 
2012). 
Transplantations of NSCs have improved cognition and memory in many AD mouse models 
according to a meta-analysis (Wang et al., 2015b) and were also shown to be effective for HD 
(Armstrong et al., 2000) and for MS (Pluchino et al., 2005). Of note, in the MS model, the NSCs 
were homing to demyelinated areas, differentiated locally and there was also evidence for anti-
inflammatory effects of the NSCs themselves. For ALS, transplantation of NSCs is rather 
unlikely to make an impact because replacing motor neurons that functionally integrate into 
the existing network is considered difficult. Instead, astrocyte transplantation could be helpful 
since they are important for axonal growth, delivery of neurotrophic factors and neuroprotection 
(Clement et al., 2003). 
For stem cell transplantations in stroke, the biggest hurdle is the hostile ischemic environment 
(Figure 5). Thus, NSCs have been preconditioned under hypoxic conditions (Theus et al., 
2008) or pre-treated with small molecules (Sakata et al., 2012b) or cytokines (Sakata et al., 
2012a). Moreover, supporting the transplanted cells with a hydrogel as supporting scaffold has 
also proven to be beneficial (Zhong et al., 2010). Finally, NSCs overexpressing growth factors 
have also shown to additionally boost endogenous neurogenesis and promote survival 
(Bernstock et al., 2017). 
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Figure 5: NSC transplantation and endogenous NSC response after ischemic stroke 
Drawing of ischemic mouse brain and different fates of either transplanted or endogenous NSCs. 
Modified from (Bernstock et al., 2017) 
 
Besides NSCs, mesenchymal stem cells (MSCs) have also been used for ALS, HD, PD and 
AD (Wang et al., 2015b; Lo Furno et al., 2018) although most studies did not show long-lasting 
engraftment of transplanted MSCs, irrespective of the administration route and both 
undifferentiated or as neurons. Thus, it has been concluded that the main therapeutic observed 
effect seems to rely on paracrine activity rather than neural differentiation (Paul and Anisimov, 
2013). Similar results were also obtained in MSC transplantations for stroke where they were 
shown to migrate to the injury site and mainly exert their positive function via secretion of 
trophic factors and neuroprotection (Ishizaka et al., 2013; Toyoshima et al., 2015). Besides the 
research in animal models, there are also ongoing clinical trials for MSCs as a treatment for 
stroke (Toyoshima et al., 2017). 
Of note, hematopoietic stem cells (HSCs) have also been used for MS. Patients’ HSCs were 
isolated followed by irradiation therapy and subsequent autologous reconstitution of the 
immune system. The idea was to reset the immune system that had been triggered against 
the own oligodendrocytes and this method has been shown effective especially for aggressive 
forms (Atkins and Freedman, 2013). 
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Taken together, transplantations of different stem cell types in neurodegenerative disease 
models have shown promising results. Nevertheless, they have clear disadvantages 
considering the costs of (patient-specific) production of a suitable number of cells in a sterile 
controlled environment and especially in the case of patient-engineered approaches, they are 
also very time consuming. Yet, if instead endogenous cell populations could be used for 
regenerative approaches, many of these caveats would be diminished. 
 
1.3.2 Endogenous cell sources 
The two major proliferative cell populations in the adult brain are NSCs and glia (Bordiuk et al., 
2014). In case of neurodegenerative diseases, glia are known to increase their proliferation 
and ever since the discovery of reprogramming and direct conversion, they have been 
considered as a potential source for in vivo reprogramming (Li and Chen, 2016). For example, 
iPSC reprogramming factors were overexpressed in reactive glia after traumatic brain injury 
and it was shown that the glia were indeed first reprogrammed to iPSCs and then differentiated 
to NSCs and subsequently to neurons and glia (Gao et al., 2016). Furthermore, in an AD 
mouse model, reactive glia were reprogrammed to neurons in vivo by NeuroD1 (Guo et al., 
2014) and different transcription factor combinations have been proven effective for directly 
converting proliferating cells both in the cortex and in the striatum after ischemia (Grande et 
al., 2013; Yamashita et al., 2019). Yet, in vivo reprogramming still has to provide evidence for 
improvements on the behavioural level in neurodegenerative disease models. Moreover, the 
limited efficiency to target and reprogram a sufficient number of cells has been a major 
disadvantage so far accompanied by the concern that the concomitant decrease of the 
targeted glia population might be detrimental. In other words, the endogenous response of glia 
to an injury or inflammation might be necessary and beneficial for the recovery but would be 
diminished if a majority of this population was forced to convert into neurons. Without the 
supporting network surrounding them, these newly generated neurons would be likely to die 
instead of integrating into the existing circuitry.   
The other endogenous cell source for regeneration are NSCs. Regarding the discussed 
neurodegenerative diseases, this approach is particularly interesting for PD and stroke 
because they are both locally restricted neuronal losses in contrast to systemic neuronal 
degradation in AD, HD, ALS and MS. 
In PD mouse models, there is no convincing evidence for newborn neurons in the substantia 
nigra or striatum (Tande et al., 2006; Borta and Hoglinger, 2007). Nevertheless, efforts have 
been made to increase adult neurogenesis for treating PD (van den Berge et al., 2013): some 
growth factors such as BDNF (Mohapel et al., 2005), TGF-a (Cooper and Isacson, 2004) and 
FGF-2 (Peng et al., 2008) managed to increase neurogenesis, but there was no evidence of 
differentiation into DA neurons. Peptide hormone Exendin-4 was able to increase SVZ 
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neurogenesis, improved motor behaviour in a PD model and increased the number of DA 
neurons, but the results did not clearly dissect whether this was due to a rescue of DA neurons 
or increased neurogenesis (Bertilsson et al., 2008). 
For stroke, different approaches have been used to enhance neurogenesis, among them 
growth factors. Overexpression of BDNF in the SVZ promoted migration towards the ischemic 
area and improved locomotor function (Yu et al., 2013). Furthermore, drugs that reportedly 
increase BDNF expression such as atorvastatin and citalopram have shown similar results not 
only in rodent stroke models (Chen et al., 2005; Espinera et al., 2013) but also in clinical trials 
(Zhang et al., 2017). Moreover, a BDNF peptide-loop mimetic managed to reduce stroke 
volume and improved the neurological score, further corroborating BDNF as a suitable means 
to treat stroke via manipulating endogenous NSCs and neuroblasts (Gudasheva et al., 2016). 
Not only BDNF, but also other growth factors such as TGF-b1 and G-CSF have been used for 
stroke treatment, although G-CSF did not improve the stroke outcome in a meta-analysis of 
clinical trials (Ma et al., 2008; England et al., 2016). 
Besides growth factors, there have been also a number of small molecules and drugs like 
bumetanide, NGP1-01 and citicoline successfully being used to increase neurogenesis, 
reduce stroke volume and/or improve sensorimotor function not only in animal models but also 
in humans (Hao et al., 2008; Alvarez-Sabin and Roman, 2013; Xu et al., 2017). 
However, all these techniques relied either on ectopic expression of growth factors that might 
have other systemic effects and local or even global administration of reagents that most likely 
did not only exert their function on neurogenesis. A direct manipulation of increasing NSC 
proliferation without the accompanying potential side effects of other treatments is still missing 
in a stroke therapeutic approach. 
The aforementioned 4D overexpression developed in our lab to specifically increase NSC 
proliferation in the SVZ or SGZ is representing such a suitable candidate. Recently, Berdugo 
Vega et al. found that 4D overexpression in SGZ NSCs in the context of ageing both increased 
neurogenesis and improved performance in hippocampus-dependent tasks (Berdugo-Vega et 
al., 2020). This is a first indication that the 4D-mediated overexpression in NSCs cannot only 
be beneficial under physiological conditions but could potentially also be used to replace lost 
neurons due to diseases or injuries.  
Regarding the disease model to test this hypothesis, stroke can be considered as most 
reasonable candidate because it is an inducible model thus allowing the experimenter to 
decide when the injury occurs and to some extend also where and how big depending on the 
model. Moreover, stroke is a single instant injury that might be more suitable for an initial 
treatment test as opposed to other models like AD, PD, HD, ALS or MS. These diseases 
systemically affect either big brain structures, the whole brain or even the entire central 
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nervous system (CNS) and are often characterized by accumulative effects over the life-span 
of the animal or patient. Thus, increasing neurogenesis in one or even both neurogenic niches 
with 4D is much more likely to demonstrate significant improvements after a locally confined 
damage like in stroke. 
Yet, the current methods of overexpressing 4D are not suitable for clinical applications since 
they rely on both transgenic animals and integrating lentiviruses accompanied by the risk of 
insertional mutagenesis. Thus, choosing a different viral strategy for this gene therapy 
approach is preferable. 
 
1.4 Gene therapy approaches in the CNS 
Ever since the discovery of virus-mediated gene transfer (Rogers and Pfuderer, 1968), the 
term ‘gene therapy’ has been formed representing the idea of therapeutical use of viruses to 
either replace defective genes or to introduce new genes to treat or cure diseases. Of note, 
also non-viral methods were developed and since they followed the same idea of introducing 
genetic material into cells, the name gene therapy is still used in this context. 
 
1.4.1 Non-viral gene therapy 
Non-viral gene therapy can be categorised in two ways, by the kind of genetic material that is 
being transferred and by the vector material that is being used. Not only DNA, either in form of 
plasmids or oligonucleotides but also RNAs (mostly small interefering (siRNA) or short hairpin 
(shRNA)) have been delivered to cells in vivo using different categories of so-called “vectors” 
ranging from cationic liposomes and lipid nanoparticles to cationic polymers (Pahle and 
Walther, 2016; Shim et al., 2018). 
Remarkably, the first non-viral gene therapy attempts were very simple and consisted of 
intramuscular injection of pure plasmid DNA (Manthorpe et al., 1993) that was shown to be 
more effective than viruses (Davis et al., 1993; Draghia-Akli et al., 1997; Horton et al., 1999). 
Hydrodynamic tail vein injection in mice was also demonstrated for plasmid DNA delivery 
mainly to the liver (Liu et al., 1999) that has also been used more recently for genome editing 
with the CRISPR/Cas9 system (Yin et al., 2014). 
For gene delivery to skin cells, cationic liposome complexes were injected into tumour tissue 
of melanoma patients and proved gene expression (Nabel et al., 1993). In another study, 
injection of only plasmid DNA obtained similar results (Heinzerling et al., 2005). 
More recently, RNAi was conducted in liver cells by injection of lipid nanoparticle-packaged 
siRNAs (Nair et al., 2014; Butler et al., 2016). Furthermore, oral administration of calcium 
pectinate-coated cationic polymer microbeads in rats achieved gene delivery to colon cells 
highlighting the complex degree of chemical engineering that can be accomplished (Bhatt et 
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al., 2015). Of note, systemic administration of oligonucleotides to target liver cells is in clinical 
trial phases I/II (Sehgal et al., 2013). 
Non-viral gene therapy has the advantage of lower potential immunogenicity and no integration 
into the host genome. However, transduction efficiencies are typically low and long-term 
sustained gene expression is not always achievable. Thus, depending on the goals, non-viral 
gene therapy may or may not be an alternative to virus-based methods. 
Moreover, targeting cells of the CNS is more challenging and has only been achieved by 
injection of a cationic polymer-complexed plasmid into the brain of newborn mouse pups 
(Boussif et al., 1995). 
 
1.4.2 Virus-based gene therapy 
The first gene therapy on humans was conducted in 1990 and famously cured two patients 
with severe combined immuno-deficiency (Blaese et al., 1995). The general concept of all viral 
gene therapy approaches is creating so-called recombinant viruses. These have the same (or 
even engineered/modified) transduction capacities as their wildtype counterparts but are made 
replication-deficient, typically by removing viral genome parts that are not necessary for gene 
expression or single-time transduction. Yet, the early use of viruses still harboured a lot of risks 
for replication-competent viruses and has been improved drastically since then.  
Below, the most common types of viruses used for gene therapy will be discussed, both with 
their advantages and disadvantages. 
 
1.4.2.1 Retroviruses 
Retroviruses are single-stranded RNA-based viruses and human immunodeficiency virus 
(HIV) is probably the most famous member of this family. Retroviral particles are 100 nm in 
diameter and are comprised of both an inner protein capsid structure and an outer lipid-based 
envelope originating from the plasma membrane of their host cell. Upon transduction of a new 
host cell, those viruses reverse transcribe their single-stranded RNA genome into double-
stranded DNA and ultimately integrate into the host genome (Kotterman et al., 2015a). 
The two mainly used genera for gene therapy approaches among retroviruses are the  
g-retrovirus and the lentivirus. One important difference between those two is the type of cells 
they can transduce. While g-retroviruses can only transduce dividing cells for integrating their 
genome into the host DNA, lentiviruses are able to achieve this task in a cell division 
independent manner (Naldini et al., 1996). 
This is an important difference when considering what kind of cells shall be transduced for 
gene therapy. g-Retroviruses have the advantage of being specific to dividing cells whereas 
lentiviruses can show a much broader tropism. This can also be manipulated depending on 
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what kind of envelope is being used during production of these viruses. Typically, the envelope 
of vesicular stomatitis virus glycoprotein G (VSV-G) is used in this process called pseudotyping 
(i.e. packaging a virus in a different envelope as compared to its naturally occurring 
counterpart), but other pseudotypes can turn out to be useful in particular cases (Joglekar and 
Sandoval, 2017). 
Their packaging capacity is around 8-10 kb based on the viral genome size which is enough 
for the majority of single gene expression cassettes or even multiple smaller genes. 
The safety of retroviruses in gene therapy has improved over the past decades since their 
initial use, leading to different generations of recombinant retroviruses. The major 
improvements consisted of reducing the amount of original viral genome to the bare minimum 
needed for gene transfer and separating the in trans supplied viral genes for viral production 
into different plasmids in order to avoid assembly of replication-competent viral particles. Thus, 
the only major drawback of these viruses nowadays is their random integration into the host 
genome accompanied by the risk of disruption of an important gene or dysregulation of its 
expression (Naldini, 2015). Remarkably, there is ongoing research about non-integrating 
lentiviral vectors although there is still a lot to optimise before potential clinical usage (Shaw 
and Cornetta, 2014; Shaw et al., 2017). 
 
1.4.2.2 Adeno- and Adeno-associated viruses 
The family of adenoviruses (AVs) are double-stranded DNA viruses and with 90-100 nm very 
similar in size to retroviruses. In contrast to retroviruses, AVs do not have an envelope but only 
a protein capsid and do not integrate into the host genome after entering the cell. Since their 
genome can be imported through the nuclear pores into the nucleus, they do not rely on cell 
division and thus can transduce both dividing and non-dividing cells. Yet, when used in gene 
therapies, one major drawback is their high immunological response compared to retroviruses 
(Wilson, 2009). On the other hand, AVs have a considerably bigger genome size of ~36 kb. 
Depending on the production strategy for gene therapy approaches, their packaging capacity 
ranges from ~36 kb (helper virus-dependent) to only 8 kb (helper virus-independent) 
(Choudhury et al., 2017).  
Adeno-associated viruses (AAVs) are small (25 nm diameter) single-stranded DNA viruses 
that have first been identified as contaminants of AV preparations (Atchison et al., 1965). 
However, they are not related to AVs since AAVs belong to the family of parvoviruses. AAVs 
have a protein capsid without a surrounding envelope and several receptors on the capsids 
have been identified. These so-called different serotypes of AAVs were isolated either from 
humans or other mammals and all show specific tropisms. Once entered into a dividing or non-
dividing host cell, AAVs can persist as episomal DNA in the nucleus or integrate into the host 
genome mainly in a viral protein-dependent manner (Salganik et al., 2015). 
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Based on their small packaging capability of ~4.8 kb, they have limited use for gene therapy 
approaches. If the gene expression cassette of interest is within that range, AAVs have several 
advantages over retro- and adenoviruses: (I) very low immunogenicity, (II) no integration into 
the host genome for recombinant AAVs (rAAVs) and (III) a big variety of available serotypes. 
This set of serotypes is even further extended because researchers have developed different 
techniques in order to mutate the capsid proteins thus leading to engineered serotypes that 
are able to transduce the cell type of choice (Kotterman and Schaffer, 2014; Grimm and 
Zolotukhin, 2015). 
 
In conclusion, rAAVs are one of the best choices for clinical gene therapy studies because of 
their aforementioned advantages as long as the packaging capacity is not a limiting factor. 
Due to their non-integrative nature, rAAVs should be used with caution for targeting dividing 
cell types such as stem and progenitor cells as they could get diluted out over cell divisions. 
Depending on the aim of the gene therapy, this might impede long-term gene expression. 
 
1.5 Aim of the thesis 
The aim of the thesis was to test 4D overexpression in mouse NSCs in vivo for its possible use 
in treatment of stroke for future clinical applications. 
To this end, I intended to develop a 4D overexpression system in mice that allowed its potential 
transfer to humans in one of the two mammalian neurogenic niches (SVZ or SGZ). Due to their 
low immunogenicity and non-integrative nature, rAAVs were chosen as the ideal approach. 
However, the big variety of available serotypes and their limited packaging capacity required 
thorough screening and careful construct design in order to achieve NSC transduction in vivo. 
Subsequently, the identified serotype candidate had to reproduce the basic hallmarks of the 
4D effect on NSCs (i.e. increase in proliferation of NSCs and progenitors and increased 
number of newborn neurons) while dealing with potential hurdles of dilution of the virus over 
cell divisions. 
Two different models of stroke – the photothrombotic and ET-1 stroke – were assessed on the 
histological level while testing the mice in different behavioural tasks. The more suitable model 
in terms of reproducibility and robustness of its effect would then be chosen for ultimately 
testing rAAV-mediated 4D overexpression in NSCs as a potential treatment for stroke in mice 
with possible applications to humans in the future. 
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2 .  M A T E R I A L S  A N D  M E T H O D S  
2.1 Materials 
2.1.1 Bacteria, cell and mouse strains 
Table 1: Bacteria, cell and mouse strains 
Bacteria, cell or mouse strain Supplier 
One Shot™ TOP10 
Chemically Competent E. coli 
Thermo Fisher Scientific 
AAV293 Stratagene 
C57BL/6JRj Janvier Labs 
R26R-Confetti Gift from Ader lab, CRTD 
 
2.1.2 Plasmids 
Table 2: Plasmids 
Plasmid Source 
p6nts-GFPloxpNLS4Dloxp Artegiani et al., 2011 
pAAV, pHelper and pRC2 Gift from Mansfeld lab, BIOTEC 
pRC9 and pRCrh10 Penn Vector Core, University of Pennsylvania 
pRCr3.45 Gift from Schaffer lab, University of California Berkely 
pMC-Cre Gift from Anastassiadis lab, BIOTEC 
pRFPnls Lange et al., 2009 
 
2.1.3 Primers 
All primers were purchased from Eurofins. Restriction sites are underlined. 
Table 3: List of primers 
Primer name Sequence (5’-3’) 
AgeI CMV pr. rev CAAGACCGGTAGCTCTGCTTATATAGACCTC 
ApaI 3xStop-polyA fw TAATGGGCCCTGATAATGAGATCCAGACATGATAAG 
ApaI Cre rev TATAGGGCCCATCGCCATCTTCCAGCAGGC 
BsrGI GFP-3xStop-pA fw CAAGTGTACAAGTGATAATGAGATCCAGACATGATAAG 
BsrGI-SV40pA rev GTAATGTACAGAACTTGTTTATTGCAGC 
Cre qPCR fw GTTTCCCGCAGAACCTGAAGATG 
Cre qPCR rev CATTGCTGTCACTTGGTCGTGG 
EcoRI CMV pr. fw CAATGAATTCCGTTACATAACTTACGGTAAATG 
FseI polyA fw CAAGGGCCGGCCGATCCAGACATGATAAG 
FseI polyA rev CTAAGGCCGGCCAACTTGTTTATTGCAGC 
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GFP qPCR fw CAGAAGAACGGCATCAAGGT 
GFP qPCR rev GTGCTCAGGTAGTGGTTGTC 
HindIII Cre fw 
CACGAAGCTTGCCACCATGCCCAAGAAGAAGAGGAAGGT 
GTCC 
NotI polyA rev CAATGCGGCCGCAACTTGTTTATTGCAGC 
NotI Ub. pr fw CAATGCGGCCGCGAATTCTGGCCTCCGC 
SacI polyA rev CAAGGAGCTCAACTTGTTTATTGCAGC 
 
2.1.4 Chemicals, buffers and culture media 
Chemicals were purchased from Invitrogen, Life Technologies, Merck, Roche or Sigma-
Aldrich. 
Table 4: Buffers and solutions for general usage 
Solution Composition 
AAV cell lysis buffer 
50 mM Tris-HCl pH 8.5 
150 mM NaCl 
2 mM MgCl2 
Endothelin-1/L-NAME 
5.7 µg/µl L-NAME  
2 µg/µl Endothelin-1 
in PBS 
2xHBS buffer 
280 mM NaCl 
1.5 mM Na2HPO4 
50 mM HEPES 
in H2O, pH adjusted to 7.05 with NaOH 
Ketamine/xylazine 
0.5 ml 10 % ketamine 
0.25 ml xylazine 
0.75 ml 0.9 % NaCl 
10 µl per g mouse body weight 
PBS 
137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
in H2O, pH adjusted to 7.4 with HCl 
4 % PFA 4 % paraformaldehyde in PBS 
TAE Purchased as 50xTAE, diluted 1:50 in H2O 
1xTE pH 7.5 
500 µl 1 M Tris-HCl pH 7.5 
100 µl 0.5 M EDTA pH 8.0 
49.4 ml H2O 
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Table 5: Culture media 
Medium Composition 
DMEM growth medium 
DMEM (Gibco) supplemented with 
10% (v/v) fetal bovine serum (FBS) 
100 U/ml penicillin-streptomycin 
Freezing medium 
50 % (v/v) DMEM 
40 % (v/v) FBS 
10 % (v/v) DMSO  
LB agar (BIOTEC media kitchen) 1.5 % agar in LB medium 
LB medium (CRTD media kitchen) 
1 % (w/v) tryptone 
0.5 % (w/v) yeast extract 
171 mM NaCl 
in H2O, pH adjusted to 7.0 
SOC medium 
2 % w/v tryptone 
0.5 % w/v yeast extract 
8.56 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
20 mM glucose 
in H2O, pH adjusted to 7.0 
 
Table 6: Iodixanol solutions for rAAV gradient purification 
Reagent (final 
concentration) 
15 % solution 25 % solution 40 % solution 58 % solution 
60 % (v/v) 
iodixanol stock 
12.5 ml 20.83 ml 33.8 ml 50 ml 
10x D-PBS (1x) 5 ml 5 ml 5 ml - 
5 M NaCl (1 M) 10 ml - - - 
1 M MgCl2 (1 mM)  50 µl 50 µl 50 µl 50 µl 
1 M KCl (2.5 mM) 125 µl 125 µl 125 µl 125 µl 
0.5 % Phenol red 75 µl 100 µl - 25 µl 
H2O            22.25 ml 23.895 ml 11.025 ml - 
S 50 ml 50 ml 50 ml 50 ml 
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Table 7: Solutions for SDS-PAGE and silver staining 
Solution Composition 
Basic developer solution 
30 g/l K2CO3 
0.00125 % (w/v) Na2S2O3 
0.00025 % (v/v) formaldehyde (added 
maximum 1 h before use) 
in H2O 
Fixation solution 
30 % (v/v) ethanol 
10 % (v/v) acetic acid 
in H2O 
2x Laemmli buffer 
4 % (w/v) SDS 
20 % (v/v) glycerol 
120 mM Tris-HCl pH 6.8 
0.02 % (w/v) bromophenol 
in H2O 
before use, add 10 % (v/v) 
2-mercaptoethanol 
NuPAGE™ MOPS SDS running buffer 
(20X) 
Purchased from ThermoFisher Scientific, 
diluted 1 : 20 in H2O 
Stop solution 
4 % (w/v) Tris 
2 % (v/v) acetic acid 
in H2O 
 
Table 8: Solutions for immunohistochemistry 
Solution Composition 
Antibody solution 
10 % (v/v) donkey serum 
0.3 % (v/v) triton-x 100 
in PBS 
Blocking solution 
10 % (v/v) donkey serum 
0.5 % (v/v) triton-x 100 
in PBS 
Cryoprotectant solution (CPS) 
25 % (v/v) ethylenglycol 
25 % (v/v) glycerol 
10 % (v/v) 10xPBS 
in H2O 
1000xDAPI 0.1 % (w/v) DAPI in H2O 
Quenching solution 0.1 M glycine pH 7.4 in PBS 
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2.1.5 Antibodies 
Table 9: Primary antibodies 
Antigen Species Supplier Catalog number Dilution 
BrdU rat Abcam ab6326 1:250 
Ctip2 rat Abcam ab18465 1:300 
DCX guinea pig Merck Millipore AB2253 1:500 
GFP goat Rockland 600-101-215 1:500 
Iba1 rabbit Wako 019-19741 1:1000 
Nestin mouse BD Biosciences 556309 1:100 
NeuN rabbit Abcam ab104225 1:1000 
S100b rabbit Abcam ab14688 1:1000 
Sox2 goat SantaCruz sc-17320 1:100 
 
Fluorophore-conjugated (DyLight or Alexa) secondary antibodies were IgG raised in donkey 
against goat, guinea pig, mouse, rabbit and rat and all purchased from Jackson 
Immunoresearch. 
 
2.1.6 Kits and enzymes 
Table 10: Kits and enzymes 
Kit/enzyme Supplier Catalog number 
Antarctic Phosphatase NEB M0289S 
Benzonase Merck 70746-3 
Click-iT Edu Alexa Fluor 647 
Imaging Kit 
ThermoFisher Scientific C10340 
DNase I NEB M0303S 
iQTM SYBR® Green Supermix Bio-Rad 170-8880 
Proteinase K, Molecular Biology 
Grade 
NEB P8107S 
Q5® High-Fidelity 2X Master Mix NEB M0492S 
QIAGEN® Plasmid Maxi Kit Qiagen 12162 
QIAprep Spin Miniprep Kit Qiagen 27104 
QIAquick Gel Extraction Kit Qiagen 28704 
QIAquick PCR Purification Kit Qiagen 28104 
Restriction enzymes NEB  
T4 DNA ligase NEB M0202S 
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2.2 Methods 
2.2.1 Cloning 
2.2.1.1 Polymerase chain reaction (PCR) 
For amplification of DNA for cloning purposes, the following PCR mix was used: 
12.5 µl  2x Q5 Master Mix 
1.25 µl  10 µM primer fw 
1.25 µl  10 µM primer rev 
~1 ng  plasmid DNA 
up to 25 µl H2O 
PCR program:  
1. Initial Denaturation 
98˚C 30 s  
            2. Amplification (35 cycles)  
98˚C 10 s 
Tm 20 s (Tm: melting temperature of respective primer pair) 
72˚C 30 s/kb of PCR product 
            3. Final extension  
72˚C 120 s 
4˚C ¥ 
The resulting PCR product was visualised using Agarose gel electrophoresis (see below) and 
the band of expected size was either extracted out of the gel (QIAquick Gel Extraction Kit) or 
the PCR mix (QIAquick PCR Purification kit) in case there was only one visible band. 
 
2.2.1.2 Restriction hydrolysis 
For restriction hydrolysis of plasmid DNA, 
1 µg  plasmid DNA  
2 µl  10x buffer  
0.2 µl  restriction enzyme  
up to 20 µl  H20  
were mixed together and incubated for 1 h at 37˚C and then heat inactivated according to the 
conditions of the respective enzyme. For PCR products, 500 ng of DNA was used and the 
incubation was extended to 2 h at 37˚C. Subsequently, the resulting ends were 
dephosphorylated in case of the plasmid DNA by adding 
2 µl  10x AP buffer  
1 µl  antarctic phosphatase (AP) 
to the DNA, followed by a 30-min incubation at 37˚C. Finally, AP was heat inactivated at 80˚C 
for 2 min. 
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The different resulting fragments of plasmid DNA were separated by Agarose gel 
electrophoresis and the respective band was extracted out of the gel. 
Restriction hydrolysed PCR products were purified using the PCR Purification Kit. 
 
2.2.1.3 Agarose gel electrophoresis 
For visualisation of DNA fragments, an agarose gel was prepared as follows: 
 x g Agarose (x = 0.5 g for 1 % or x = 2 g for 2 % Agarose) 
 50 ml  1xTAE buffer 
For DNA fragments <1kb to be resolved, a 2 % agarose gel was prepared, for bigger 
fragments, the 1 % agarose gel was used. The solution was boiled in the microwave until the 
agarose was completely dissolved, briefly cooled down and then 1:10,000 SYBR Safe DNA 
gel stain (Invitrogen) was added. The agarose solution was poured into a chamber with a comb 
to form the lanes. After the gel was solidified, the comb was removed and the gel placed into 
an electrophoresis chamber filled with 1xTAE buffer. Samples and a 1 kb marker GeneRuler 
were loaded into the lanes and electrophoresis was conducted at 90 V for 60-90 min. DNA 
was visualised afterwards on a gel documentation system under UV light. 
 
2.2.1.4 Ligation 
Plasmid DNA and PCR fragments were ligated after restriction hydrolysis using a 3:1 ratio 
(PCR:plasmid) with 50 ng plasmid DNA in a total volume of 20 µl, 1 µl T4 Ligase and 2 µl 
10x ligase buffer. Incubation was conducted over night at 16˚C, followed by heat inactivation 
the next day at 65˚C for 10 min. The ligation mix was then stored at 4˚C until transformation. 
 
2.2.1.5 Heat-shock transformation 
For heat-shock transformation of ligated plasmid DNA, 50 µl competent cells (E.coli TOP10) 
were thawed on ice. Two µl of DNA was added to the cells and the tube was flicked for a few 
times. After incubation on ice for 30 min, the heat-shock was conducted in a water bath at 42˚C 
for 30 s followed by immediate chilling on ice for at least 2 min. Then, 950 µl SOC medium 
was added and the bacteria were incubated on a shaker at 950 rpm at 37˚C for 1 h. One 
hundred µl of transformed bacteria were spread on a LB agar plate with antibiotics according 
to the plasmid and incubated over night at 37˚C. 
 
2.2.1.6 MiniPrep 
A single colony of transformed bacteria grown on an LB agar plate over night was picked and 
transferred to 1.9 ml LB medium and appropriate antibiotics and shaken over night at 950 rpm 
and 37˚C. The next day, 500 µl of the bacterial culture were stored at 4˚C and the rest was 
used for plasmid isolation using the Qiagen MiniPrep Kit. Plasmids were eluted from the 
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column using 50 µl nuclease-free H2O and stored at -20˚C or immediately used for analysis of 
the cloning by restriction hydrolysis or sequencing. 
In case of a positive clone and confirmed sequence, 500 µl glycerol was added to the 
remaining 500 µl bacterial culture and this glycerol stock was stored at -80˚C.  
 
2.2.1.7 MaxiPrep 
Bacteria from a glycerol stock were inoculated into 250 ml of LB medium with appropriate 
antibiotics and shaken at 220 rpm and 37˚C over night. Plasmids were isolated using the 
MaxiPrep Kit from Qiagen following the QuickStart protocol with the following modifications: 
Step 5: Centrifugation at 10,000 g for 10 min at 4˚C, then supernatant was filtered using 
Qiagen Maxi Cartridges and loaded onto the column 
Step 11: Centrifugation was extended to 30 min 
Step 12: 200 µl nuclease-free H2O were used to dissolve the plasmid per 250 ml LB 
culture used 
MaxiPrep-isolated plasmids were analysed on a NanoDrop machine to determine purity and 
concentration of the DNA and then stored at -20˚C. 
 
2.2.1.8 Constructs and cloning strategy 
In order to achieve overexpression of Cdk4, Ccnd1 and GFP as a reporter protein (Ub4D, 
Figure 6), the Glox4D expression cassette from Artegiani et al. was used as a template 
(Artegiani et al., 2011). The polyA (pA) sequence was introduced using the FseI restriction site 
and pRFPnls as a PCR template (Lange et al., 2009). Subsequently, the resulting construct 
was PCR-amplified from the ubiquitin promoter to the pA sequence using primers flanked by 
NotI-restrictions sites and subcloned into a pAAV backbone containing AAV2 ITRs. 
The UbGFP construct was created by inserting a pA fragment with three upstream Stop 
codons into the BsrGI restriction site of the Ub4D construct. This resulted in a remaining partial 
out-of-frame Cdk4 and a full Ccnd1 coding sequence downstream of the pA. 
For the CMV-GFP construct, the CMV promoter was PCR-amplified from the pAAV plasmid 
and subcloned into the EcoRI and AgeI restriction sites of UbGFP. 
For UbCre4D, cre was PCR-amplified from pMC-Cre and replaced GFP in the Ub4D construct 
using HindIII and ApaI restriction sites. 
UbCre was obtained by PCR amplification of the 3xStop Codon-polyA sequence from UbGFP 
and cloning it into the ApaI and SacI restriction sites of UbCre4D. 
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Figure 6: rAAV constructs 
rAAV expression cassettes of all cloned constructs in scale are shown. 
 
2.2.2 rAAV 
2.2.2.1 Cell culture of AAV293 
AAV293 cells were purchased from Stratagene (La Jolla, USA) and thawed in a 37˚C water 
bath. The cell suspension was mixed by pipetting up and down and then added to 10 ml DMEM 
growth medium and centrifuged at 200 g for 3 min at room temperature (RT). The resulting cell 
pellet was resuspended in new DMEM growth medium and cells were cultured at 37˚C and 
5.0 % CO2. When reaching a confluence of ~50 %, cells were washed once with PBS and then 
detached from the cell culture vessel by adding Trypsin/EDTA for 2 min at 37˚C. Cells were 
flushed off with DMEM growth medium, pellet by centrifugation at 200 g for 3 min at RT and 
then distributed into a new vessel at a split ratio of approx. 1:10. Alternatively, cells were frozen 
(~106 cells/vial) in freezing medium and cryo vials for long-term storage. 
 
2.2.2.2 CaPO4 transfection 
Twenty-four hours prior to CaPO4 transfection, AAV293 cells were detached as described 
above, counted with a hemocytometer and ~3x106 cells per 10 cm dish were seeded in 10 ml 
DMEM growth medium. Plasmids for transfection (pAAV, pHelper and one of the serotype 
plasmids pRC2, pRC9, pRCrh10 or pRCr3.45, 5 µg per plasmid per 10 cm dish) were adjusted 
to a concentration of 1 µg/µl with TE pH 7.5 and diluted in 1 ml 0.3 M CaCl2 per 10 cm dish. 
Subsequently, the CaCl2-DNA mixture was added dropwise to 1 ml of 2xHBS buffer, mixed 
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gently and then added dropwise to the 10-cm dish containing 10 ml DMEM growth medium 
and the AAV293 cells seeded the day before. The medium was replaced with new DMEM 
growth medium 7-8 hours after transfection and the cells were incubated at 37˚C and 5.0 % 
CO2 for a total of 72 hours after transfection. 
 
2.2.2.3 rAAV harvest and purification 
Seventy-two hours after transfection, 125 µl 0.5 M EDTA pH 8.0 per 10-cm dish was added to 
the cells and they were incubated for 10 min at RT. Then, cells were flushed off the dishes, 
collected in tubes together with the DMEM growth medium and pelleted at 300 g for 3 min at 
RT. After a washing step with PBS and another centrifugation at 300 g for 3 min at RT, the 
cells were resuspended in 500 µl AAV lysis buffer per 10 cm dish. Cells were lysed with four 
freeze/thaw cycles using a dry-ice/ethanol bath and a 37˚C water bath. After each thawing 
step, cells were additionally vortexed for 30s. Next, cell debris was pellet at 2,500 g for 15 min 
at 4˚C and the supernatant (i.e. cell lysate) was treated with 100 U Benzonase per dish for 1 h 
at 37˚C. Followed by another centrifugation at 2,500 g for 15 min at 4˚C, the supernatant was 
loaded on top of an Iodixanol gradient comprised of four layers from top to bottom: 
8 ml 15 % iodixanol solution 
6 ml 25 % iodixanol solution 
8 ml 40 % iodixanol solution 
5 ml 60 % iodixanol solution 
The ultracentrifuge tubes were sealed and subsequently centrifuged at 63,000 rpm for 2 h at 
4˚C using a 70Ti fixed-angle rotor. The ultracentrifuge tubes were then penetrated with an 18G 
needle at the interphase between the 40 % and 60 % layer. Fractions of ~1 ml were collected 
with the needle facing bevel up. Identification of rAAV containing fractions was done by 
measuring the refractive index of each fraction and the ones with a refractive index between 
1.4000 and 1.4199 were pooled. The pooled fractions were filled up to 15 ml with PBS and 
loaded onto an Amicon Ultrafilter 15 ml 100k MWCO tube and centrifuged at 4,000 g for 1 min 
at 4˚C. Centrifugation was repeated until the remaining liquid level in the top of the tubes was 
~1 ml, then it was filled up to 15 ml with PBS again. This step was repeated another three 
times resulting in a total of four washing steps and a reduction of the iodixanol concentration 
to <0.001 %. At the end, the rAAV solution was concentrated to a final volume of ~200 µl, 
aliquoted and stored at -80˚C. 
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2.2.2.4 rAAV quantitative PCR (qPCR) titration 
rAAV sample preparation for qPCR titration 
For determining the titer of the rAAVs, they were first treated with DNase I to degrade any 
extraviral DNA using the following pipetting scheme: 
            2 µl rAAV sample     
            1 µl 10xDNase I buffer  
            1 µl DNase I (2U/µl)  
            6 µl H2O  
The samples were incubated for 30 min at 37˚C. Then, DNase I was inactivated by adding 1 µl 
50 mM EDTA pH 8.0 and incubation for 10 min at 75˚C. After briefly chilling the sample on ice, 
rAAV particles were broken open by adding the following proteinase K reagents: 
            6.5 µl H2O  
            2 µl 100 mM Tris/HCl, pH 8.0  
            0.5 µl proteinase K (20 µg/µl)  
After incubation at 55˚C for 1 h, proteinase K was heat-inactivated at 95˚C for 10 min. The 
sample was then stored on ice until the qPCR. 
 
qPCR 
For rAAV qPCR titration, the following mix was used 
            10 µl  2x iQ SYBR Mix  
4.9 µl  H2O  
            0.05 µl  100 µM primer fw 
            0.05 µl  100 µM primer rev  
            5 µl  sample 
For detecting the packaged rAAV genome, either GFP or Cre primers were used. Each sample 
was run in technical triplicates using the following program: 
1. Initial Denaturation 
95˚C 10 min  
            2. Amplification (40 cycles)  
95˚C 30 s 
60˚C 30 s (read fluorescence)  
72˚C 60 s 
            3. Dissociation curve   
95˚C 60 s 
55˚C 30 s 
continuously increasing temperature and fluorescence reading 
95˚C 30 s 
rAAV titer was determined using a standard curve of GFP or Cre plasmid, respectively.  
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2.2.2.5 SDS-PAGE and silver staining of purified rAAV 
For assessing the purity of the purified rAAV particles, SDS-PAGE followed by silver staining 
was conducted. To this end, at least 109 rAAV particles were diluted with an according volume 
of 2x Laemmli buffer and heated at 95˚C for 5 min before loading on the gel. The SDS-PA gel 
was a 4-12 % Bis-Tris gel (NuPAGE™) purchased precast from ThermoFisher Scientific and 
the samples were run at 200V for 1 h in MOPS buffer. 
Silver staining is a very sensitive method to detect very small amounts of protein in a SDS-PA 
gel and the protocol used was adapted from Chevallet et al., 2006. (Chevallet et al., 2006) 
The gel was first fixed in fixation solution for 30 min followed by over night (up to 24 h) 
continued fixation with new fixation solution. The next day, the gel was rinsed twice in 20 % 
ethanol for 10 min each and then twice in H2O for 10 min per wash. Subsequently, the gel was 
sensitized for 1 min in 0.02 % (w/v) Na2S2O3 followed by two one minute washes with water 
and impregnation of the gel with 12 mM AgNO3 for 20 min. For revealing the silver staining, 
the gel was first dipped into water for 10 s and then transferred to basic developer. The most 
intense bands usually started appearing within a few minutes, but depending on the amount 
of protein and the desired degree of staining, developing was continued up to 45 min. The 
reaction was then stopped by transferring the gel to the stop solution for 30 min. Finally, the 
gel was washed twice with water for 30 min each and then stored in water until imaging. 
 
2.2.3 Immunohistochemistry 
Free floating staining was performed on 40 µm vibratome brain sections stored in CPS at 
-20˚C. Sections were first washed twice in PBS for 10 min each and then blocked using 
blocking solution for 1.5 h at RT, followed by incubation with the primary antibodies over night 
in antibody solution at 4˚C. After 3 washes with PBS for 5, 10 and 15 min, respectively, 
secondary antibody staining was performed in antibody solution in the dark for either 4 h at RT 
or over night at 4˚C. Donkey serum and secondary antibodies were centrifuged for 10 min at 
16,000 g at 4˚C before every use. In all subsequent steps, the sections were always kept in 
the dark to prevent bleaching of the fluorophores. Next, the sections were washed once for 
10 min with PBS followed by incubation with DAPI (1:1000 in PBS) for 10 min and finally 
washed another three times with PBS for 5, 10 and 15 min, respectively. Sections were 
mounted on glass slides, and covered with cover slips using AquaPolymount. Until imaging, 
the slides were stored in the dark at 4˚C. 
For BrdU staining, the following steps after primary antibody (all antibodies except for BrdU 
antibody) incubations and the PBS washes were included. Sections were post-fixed with 
4 % PFA for 30 min and then washed three times for 10 min each with PBS. DNA was exposed 
by incubation with 37˚C pre-warmed 2M HCl for 25 min followed by three washes for 5, 10 and 
15 min, respectively with PBS. After incubation in quenching solution for 20 min, sections were 
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washed again three times with PBS for 5, 10 and 15 min, respectively. Another blocking with 
blocking solution was performed for 1 h at RT before incubation with the primary anti-BrdU 
antibody in antibody solution at 4˚C over night. The remaining protocol was the same as for a 
normal staining after the primary antibody incubation. 
For EdU staining, there were also additional steps introduced after primary antibody incubation 
and the PBS washes. The tissue was post-fixed with 4 % PFA for 30 min followed by two 
10 min wash steps in PBS + 3 % (w/v) BSA. Quenching was performed as in the BrdU protocol 
and after another 10-minute wash step with PBS + 3 % BSA, sections were permeabilised with 
0.5 % triton-x 100 in PBS for 1 h. Next, two washes with PBS + 3 % BSA were performed and 
then the EdU Click-iT reaction mix was added for 30 min. This and all subsequent steps were 
done in the dark to prevent bleaching of the fluorophore. After one more wash step with 
PBS + 3 % BSA for 10 min and two washes with PBS for 10 min each, the standard protocol 
was continued with secondary antibody incubation (see above). 
 
2.2.4 Animals 
Animals were housed in standard cages with a 12h:12h light:dark cycle and had access to 
water and food ad libitum. All procedures were performed according to local regulations 
(TVV13/2016 and TVV39/2018). 
 
2.2.4.1 Stereotaxic injection 
For rAAV or Endothelin-1/L-NAME injection, a stereotaxic system was used (Kopf 
Instruments). Mice were anaesthetised in a chamber filled with oxygen and 3 % isoflurane and 
then mounted on the stereotaxic frame with continuous supply of the oxygen/isoflurane mixture 
for sustained anaesthesia. The body was placed on a heating pad to ensure maintenance of 
the body temperature during the surgery. The head was fixed using the ear bars and mice 
were injected with 100 µl painkiller (carprofen) subcutaneously. Eyes were prevented from 
drying out by applying protective creme and the head was shaved with a scalpel after ethanol 
disinfection before the skull was exposed by a small surgical incision on top of the head. After 
identification of bregma and adjusting the mouse’s head in a flat orientation, coordinates for 
the respective injection location were marked and a ~1 mm hole was drilled (Table 11). A glass 
capillary mounted on a microinjector pump was filled with paraffin oil, PBS and then virus or 
ET-1 and slowly inserted into the brain until the respective depth needed. After injecting the 
required volume and 5 minutes waiting time, the capillary was slowly pulled out and the skin 
was closed using surgical single stitches. After applying antiseptic solution on top of the skin, 
the mouse was released from the frame and placed into its cage under red light until waking 
up under surveillance.  
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Table 11: Coordinates for stereotaxic injections 
Targeted area 
Coordinate 
direction 
Coordinates (in mm 
from bregma) 
Injected volume 
and speed 
Dentate gyrus 
rAAV injection 
medial-lateral ± 1.600 
1000 nl, 200 nl/min anterior-posterior -  1.900 
dorsal-ventral -  1.900 (from pia) 
Lateral ventricles 
rAAV injection 
medial-lateral ±  0.700 
4000 nl, 250 nl/min anterior-posterior +  0.400 
dorsal-ventral -   2.500 (from pia) 
Striatum 
ET-1 single injection 
medial-lateral ±  1.800 
500 nl, 100 nl/min anterior-posterior +  0.700 
dorsal-ventral -   3.000 (from pia) 
Striatum 
ET-1 double injection 
medial-lateral 
(I)  ± 1.500 
(II) ± 1.800 
500 nl, 100 nl/min 
at each site 
anterior-posterior 
(I)  + 1.100 
(II) + 0.200 
dorsal-ventral 
(I)  - 2.500 (from pia) 
(II) - 2.800 (from pia) 
 
2.2.4.2 Perfusion 
At the end of an experiment, mice were anaesthetised with an i.p. injection of 
ketamine/xylazine and perfused with 4 % PFA as follows. As soon as the mouse reached deep 
anaesthesia level (no toe-pinching or eye-twitching reflex), needles were poked through its 
fore limbs to fix it on a styrofoam board. The thorax was opened and the still beating heart was 
exposed and a blunt needle connected to a pump was inserted into the left ventricle. A small 
incision in the right atrium was made and then 0.9 % (w/v) NaCl solution pumped through the 
blood vessel system. After ~50 ml of saline solution, the pump was switched to 4 % PFA for 
fixation of the mouse. Once the body was stiff, perfusion was stopped, the mouse dissected 
and the brain was stored in 4 % PFA over night at 4˚C. The next day, the brain was washed 
twice with PBS and then stored in PBS at 4˚C until it was cut in 40 µm sections using the 
vibratome. 
 
2.2.4.3 Novel object recognition (NOR) task 
In the NOR task, certain aspects of learning and memory can be assessed (Lueptow, 2017). 
Mice were placed individually into a multi-conditioning box (TSE) with a square-shaped arena 
and a camera on top. On the training day, two identical objects were placed in two opposite 
corners and mice were positioned into one of the other corners and subsequently allowed to 
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explore the environment freely for 5 min. The time the animal was exploring either of the 
objects was recorded. The next day, one of the two objects was exchanged with a different 
one and mice were again exploring for 5 min and exploration time was recorded. The same 
procedure was repeated with another new object on the next day. The training object that was 
considered the old object on the second and third day was a water filled 250 ml glass bottle 
with a blue lid, the first new object a pink liquid filled 250 ml glass bottle with a green lid and 
the new object on the last day was a water filled 250 ml plastic bottle with an orange lid. 
 
2.2.4.4 Corner test 
The corner test was originally developed by (Zhang et al., 2002) to assess sensorimotor 
dysfunction after unilateral brain damage caused by ischemic stroke. The setup was built 
based on the modifications made by (Hao et al., 2008). A parallelogram-shaped box with 
angles of 30˚ and measures of 20x35x20 cm (length x width x height) was built in-house and 
mice were tested during their night cycle for more active behaviour. 
A mouse was placed in the middle of the box and filmed from top under red light. Once the 
mouse approached one of the two narrow corners ten times with a clear result of turning either 
left or right, the trial was finished. The video analysis was conducted blinded regarding the 
treatment of the mouse and the read-out was percentage of ipsilateral turns relative to the 
stroke/PBS injected hemisphere. 
 
2.2.4.5 Catwalk 
The Catwalk system (Noldus) is typically used in quantitative analysis of gait and locomotion 
of mice and rats. It consists of a 1.2 m long glass platform with green light shining through its 
side. A corridor is created by two adjustable walls and there is red light on top for optimal 
contrast for the camera attached to the system below. The mouse is placed on one end of the 
corridor whereas there is a goal box on the other side containing a hole in the bottom leading 
to its home cage. When the mouse walks over the glass platform, the green light is deflected 
down which is dependent on how much weight the mouse is putting on each paw. The catwalk 
system automatically detects the mouse and films the run, enabling later software-supported 
analysis of a plethora of parameters related to gait analysis (e.g. speed, pressure of each paw, 
stride length, paw placement etc).  
The following three days training protocol before stroke was established. The first day, mice 
were allowed to freely explore the catwalk for three trials with two min each introducing them 
to the goal box at the end of each run. The day after consisted of a total of five trials. The first 
two were again free exploration trials of one minute each. The last three trials, mice were not 
allowed to turn around anymore and if they did, the trial was aborted and mice were guided to 
the goal box. The goal was to have the mouse run once across the glass platform without 
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stopping or turning around in between since this would cause a “non-compliant” trial for the 
software and would require repetition. The last day of training was also used as baseline values 
for after stroke. On this day, mice had to complete 6 compliant trials (running in one direction 
only) with an average speed of at least 25 cm/s and less than 60 % speed variance. Once this 
was achieved, stroke could be induced the following days and mice were subsequently tested 
once per week with the same requirements as on day three of training. 
 
2.2.4.6 Rotarod 
The accelerating rotarod (Intelli-Bio) was used for assessing motor coordination of mice after 
stroke. It consisted of a cylinder with ~3 cm diameter that was separated by 20 cm diameter 
disks into 5-6 cm wide lanes. The cylinder had a rough surface enabling good grip for the mice. 
This setup was built 20 cm above a platform used to detect the fall of the animal. The cylinder 
was set to a starting speed of 3 rpm and once all mice of one trial were placed into their 
respective lane facing forward, the trial was started. This caused the rotarod to constantly 
accelerate over the total trial length of 300 s reaching an end speed of 30 rpm. A trial was 
finished once all mice either fell within these 300 s or managed to stay on the cylinder for 20 s 
at the maximum speed. As a readout, the time a mouse managed to stay on the cylinder was 
used and expressed as “latency to fall” in s. 
Different training protocols were tested varying the number of trials per day (3 or 5), the number 
of training days (3 or 4) and increasing the acceleration after two days. In all cases, an inter-
trial-interval of at least 15 min was maintained and this interval was kept constant throughout 
one experiment. After training, mice were separated into groups ensuring a similar average 
value and standard deviation of all groups before stroke. Mice that did not manage to reach at 
least 100 s at the last day of training or did not show improvement over the course of the four 
days were excluded. The surgery was usually performed 3-4 days after the last day of training 
followed by weekly rotarod testing starting at day 7 after surgery. 
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3 .  R E S U L T S  
3.1 Establishment of a rAAV purification system for in vivo transduction of NSCs 
The first goal was to establish and optimize a production and purification protocol for rAAVs 
(Figure 7) suitable for many serotypes in order to identify one that allowed the efficient 
transduction of NSCs in vivo (adapted from (Strobel et al., 2015)). 
For production, the cell line AAV293 was used which had been derived from conventional 
HEK293 cells by selection for a larger cell surface, flattened morphology and a firm attachment 
to cell culture vessels in order to enable high titer rAAV production. The cells were transfected 
with three plasmids: the transgene carrying plasmid (pAAV), the serotype defining plasmid 
(pRC) and a ‘helper’ plasmid (pHelper) expressing essential AAV proteins. The CaPO4 
transfection was compared to the PEI transfection to determine which method resulted in a 
higher produced rAAV titer. Titration of viral particles by qPCR showed CaPO4 as the better 
transfection method which was further optimised considering the following parameters: (I) pH-
value of the CaPO4 solution, (II) seeding density of cells and (III) plasmid concentration. 
After rAAV production in the AAV293 cells (Figure 7A), the mainly intracellularly residing rAAV 
particles were released by lysing the cells via freeze/thaw cycles. Following DNase treatment, 
the cell lysate was subjected to a layered iodixanol gradient which is commonly used for 
separation and purification of cell organelles, vesicles and viruses. Here, it was used to isolate 
the packaged rAAV particles from empty virus capsids and the cell lysate. Subsequently, the 
iodixanol gradient was ultracentrifuged, the clear colourless 40 % iodixanol layer was collected 
in fractions and the refractive index of each fraction was measured. DNA-packaged rAAV 
particles reside in the 40 % iodixanol layer as opposed to empty capsids that accumulate in 
the lower end of the 25 % layer (Strobel et al., 2015). Therefore, the refractive index allowed 
to draw precise conclusions about which fractions contained 40 % iodixanol and which had 
impurities from layers above or below. Corresponding fractions were collected, pooled and 
concentrated. The purity of rAAV containing fractions and of the final concentrate was 
assessed using SDS-PAGE and subsequent silver staining, indicating that the pooled fractions 
indeed showed the three bands of the main AAV proteins (viral protein 1, 2 and 3, Figure 7B). 
As an additional quality control, the titer of the rAAV particles was routinely assessed using 
qPCR (Figure 7C). 
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Figure 7: Production and purification of rAAVs 
(A) Schematic of CaPO4 transfection for rAAV production followed by purification via iodixanol 
ultracentrifugation. (B) Silver stained SDS-PA gel of iodixanol fractions after rAAV purification. PS: pre-
stained marker. (C) Sketch of an amplification plot after rAAV qPCR titration. 
 
 
Using the method described above (Figure 7), four rAAV serotypes were generated yielding 
titers ranging from 5x108 genome copies (GC)/µl up to 1x1010GC/µl. High titer rAAVs were 
diluted so that all used viruses were in a comparable range.  
rAAVs have variable but usually low transduction efficiencies in vitro regarding different cell 
lines depending on the serotype (Ellis et al., 2013). Therefore, a comparison of the produced 
serotypes after qPCR titration was directly conducted in vivo.  
 
3.2 rAAV-4D increases SVZ NSC proliferation and OB neurogenesis 
For the first rAAV in vivo tests, a UbGFP expression cassette was cloned (Figure 8A). It 
contained the constitutive human ubiquitin C promoter driving GFP expression that was tagged 
with a nuclear localisation signal (NLS) for more precise quantification of transduced cells. Up- 
and downstream of this expression cassette were the necessary inverted terminal repeats 
(ITR) of AAV2 that allowed packaging into the rAAV particles. Stereotaxic injection of rAAVs 
into the ventricle of adult mice (Figure 8B) resulted in GFP+ cells only for serotype r3.45 among 
all the tested serotypes after one week (Figure 8D). Interestingly, although injection was done 
in only one hemisphere, the contralateral hemisphere also showed GFP+ cells lining the 
ventricle walls indicating a wide distribution of the rAAV particles within the ventricle after 
injection. A first analysis demonstrated that rAAVr3.45 transduced 1.94 ± 0.59 % of all SVZ 
NSCs that were identified as Nestin+ and S100b- (Figure 8E). 
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Figure 8: rAAV SVZ NSC transduction and 4D-mediated increase in NSC proliferation 
(A) Constructs used for rAAV ventricle injections. Ub4D coding for GFP and 4D overexpression whereas 
UbGFP only coded for GFP expression. (B) Schematic sagittal and coronal view of rAAV ventricle 
injection. (C) Timeline of mouse treatments in this experiment. ‘X’ indicates time points of sacrifices, 
EdU i.p. injections were given twice per day. (D) GFP+ (green) cells after rAAV transduction in both ipsi- 
and contralateral hemisphere. (E) Non-transduced NSCs (Nestin+ (red) and S100b - (white) cells) are 
indicated with white arrows and GFP+ NSCs with a yellow arrow (LV = lateral ventricle). Quantification 
of transduced NSCs is shown as average ± standard deviation (SD). (F) Transduced (GFP+, green) 
EdU+ (red) cells were quantified one and three weeks after injection. Average ± SD is shown in all 
graphs. **p<0.01, student’s t-test using Holm-Sidak correction. 
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In order to assess the effect of rAAV-mediated 4D overexpression, a Ub4D construct was 
cloned (Figure 8A). In this construct, the coding sequences of cdk4 and cyclinD1 were inserted 
after the NLS-tagged GFP and all three proteins were separated by two self-cleaving T2A 
peptides enabling an equimolar expression while ensuring that they were separated into three 
proteins. This expression strategy had already been used successfully in our lab using lentiviral 
transduction of SGZ NSCs and was adapted for the rAAV construct (Artegiani et al., 2011; 
Berdugo-Vega et al., 2020). The corresponding control construct UbGFP contained the same 
elements as Ub4D, however, after the NLS-tag, three stop codons were introduced followed 
by the polyA sequence, ensuring that both transcription (polyA) and translation (stop codons) 
stopped before the Cdk4-T2A-Ccnd1 fragment. Additionally, Cdk4 was only partially present 
and the whole fragment was out-of-frame with regard to the GFP reading frame. This strategy 
was chosen to make the UbGFP control construct on DNA level as similar to the Ub4D 
construct as possible both in length and sequence without expressing 4D. 
For investigating the proliferation of SVZ NSCs, mice were injected i.p. with EdU the last two 
days before sacrifice either one or three weeks after rAAV injection (Figure 8C). When 
comparing GFP vs 4D injected animals, there was a threefold increase in proliferation from 
2.90 ± 0.56 % to 9.05 ± 1.93 % (p=0.0033, multiple t-test with Holm-Sidak correction) of 
transduced EdU+ cells among all transduced cells after three weeks (Figure 8F). Of note, this 
analysis included both proliferating NSCs and progenitors since EdU is taken up by any cell in 
S phase within the 48 hours of EdU administration. 
Furthermore, the percentage of transduced DCX+ differentiating neuroblasts in the SVZ was 
similar for GFP and 4D animals both after one or three weeks (13.44 ± 3.07 % vs 11.35 ± 
2.99 % after one week, 14.13 ± 5.59 vs 15.40 ± 4.84 % after three weeks, Figure 9B). Since 
differentiating cells migrate along the RMS towards the OB, changes in neuronal output were 
assessed by quantification of BrdU+ newborn neurons in the OB birthdated the third week after 
rAAV injection (Figure 9A), where the peak in proliferation was observed (Figure 8F). Four 
weeks later, the number of total BrdU+ cells per volume in the granule cell layer of the OB 
showed a remarkable increase by 44.19 % for 4D injected animals (0.93x105 ± 0.19x105 cells 
per mm3 vs 1.34x105 ± 0.11x105 cells per mm3, p=0.0095, student’s t-test with Holm-Sidak 
correction, Figure 9C). Since this quantification was conducted irrespective of infected cells, 
this result is an underestimation of the magnitude of the 4D effect on OB neurogenesis. 
Concluding, rAAVr3.45 transduced SVZ NSCs (Figure 8E) and rAAV-mediated 4D 
overexpression increased their proliferation (Figure 8F) resulting ultimately in more newborn 
neurons in the OB (Figure 9C).  
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Figure 9: rAAV-4D mediated increase in olfactory bulb neurogenesis  
(A) Timeline of mouse treatments in this experiment. ‘X’ indicates time points of sacrifices, BrdU i.p. 
injections were given twice per day. (B) Transduced (GFP+, green) DCX+ (white) cells were quantified 
one and three weeks after injection. (C) BrdU+ (yellow) cells in the olfactory bulb were quantified 7 weeks 
after injection. Average ± SD is shown in all graphs. **p<0.01, student’s t-test using Holm-Sidak 
correction. 
 
 
Of note, there were no GFP+ cells present neither in the RMS nor in the OB in any injected 
animal. One explanation for this unexpected result could be that rAAVs and the GFP 
concomitantly get diluted out over cell divisions of the differentiating cells while migrating 
towards the OB. To address this hypothesis, a Cre-lineage tracing approach was used (Figure 
10). To this end, the well-established Confetti mouse line (Snippert et al., 2010) was used as 
a reporter (Figure 10B). 
For this lineage tracing experiment, UbCre4D was cloned which contained the same elements 
as Ub4D except for Cre recombinase instead of GFP (Figure 10A). rAAVr3.45 with UbCre4D 
was injected into the ventricle and three weeks later, animals showed fluorescent protein 
expression (YFP shown as an example) not only in the SVZ (Figure 10C) but also in the RMS 
(Figure 10D) and OB (Figure 10E). Therefore, rAAVs and/or GFP seem to get diluted out over 
the differentiation of SVZ NSCs and the migration process of their progeny. 
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Figure 10: Cre-lineage tracing in Confetti mice after rAAV-UbCre4D ventricle injection 
(A) rAAV-UbCre4D containing Cre instead of GFP. Mice were injected into the ventricle and sacrificed 
three weeks later (‘X’). (B) Schematic sagittal view of rAAV ventricle injection. (C) YFP+ cells three weeks 
after rAAV injection into the ventricle that have migrated via the RMS (D) towards the OB (E). 
 
3.3 Two rAAV serotypes efficiently transduce SGZ NSCs 
Besides the SVZ, the four produced rAAV serotypes were also tested for transduction of SGZ 
NSCs. Here, a CMV-GFP and the UbGFP control construct were used to also investigate the 
influence of the promoter on the apparent transduction efficiency of the rAAV serotypes (Figure 
11A). CMV-GFP expressing rAAVs were stereotaxically injected into the hippocampus of adult 
mice (Figure 11B) and all serotypes resulted in different GFP expression patterns that were 
qualitatively assessed (Figure 11C). While serotypes 9 and rh10 showed a high preference for 
cells in the hilus, serotype 2 was more efficient in transducing cells in the granular cell layer 
(GCL). Of note, rAAV9 was the only serotype that yielded a much higher titer after purification 
(1x1010 GC/µl as compared to 5x108 GC/µl of the other serotypes), and when injecting a high 
titer rAAV9, there were also more GFP+ cells observed in the GCL (data not shown). 
Thus, serotype 9 and the previously for SVZ NSCs used serotype r3.45 were injected in a 
second round of testing. Here, the UbGFP construct was used instead of CMV-GFP. For both 
serotypes 9 and r3.45, the majority of cells in the GCL were GFP+ additional to the hilus (Figure 
11D). Sox2+ cells were used to identify NSCs in the SGZ and the two serotypes showed a 
transduction rate of 14.33 ± 0.95 % (r3.45) and 12.45 ± 2.15 % (9) of NSCs when normalised 
to all GFP+ cells (Figure 11E). 
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Figure 11: rAAV serotype screening for NSC transduction in the hippocampal SGZ 
(A) rAAV constructs used in this experiment. (B) Schematic sagittal and coronal view of rAAV injection 
into the hippocampus of adult mice. (C) GFP expression (green) of rAAV-transduced cells using the 
CMV-GFP constructs and different serotypes one week after injection. (D) GFP expression (green) of 
rAAV-transduced cells using the UbGFP construct of serotypes r3.45 and 9 one week after injection. 
(E) Quantification of transduced NSCs (GFP+/Sox2+) normalised to all transduced cells (GFP+). SGZ = 
subgranular zone, GCL = granular cell layer. Average ± SD is shown. 
 
The identification of two suitable serotypes for SGZ NSC transduction indicated the usefulness 
of rAAVs for gene delivery and future experiments are needed to show that rAAV-4D 
expression in SGZ NSCs would lead to similar results as observed in the SVZ.  
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3.4 Establishment of an inducible striatum stroke model 
There are various stroke models being used in rodents, all of them with their advantages and 
caveats. Two inducible stroke models were established and assessed both histologically as 
well as on a behavioural level. In the photothrombotic stroke model, the photosensitive dye 
Rose Bengal is injected i.p. systemically to the mouse. For a targeted stroke in a specific brain 
area, cold light has to be shined at that area leading to local blood clot formation and ultimately 
brain ischemia. 
Endothelin-1 (ET-1) on the other hand is a small peptide that can cause local vasoconstriction 
if injected into the brain. For mice, it has been recommended to combine ET-1 with the NOS 
inhibitor L-NAME (preventing NOS-induced vasodilatation). 
For both stroke models, the striatum was targeted for several reasons. First, the SVZ and its 
residing NSCs are in close proximity to the striatum which increases the likelihood of migration 
and potential therapeutic effects upon 4D treatment later on. Furthermore, the effects of stroke 
and the neurogenic response was not only supposed to be analysed histologically but also on 
a behavioural level. To this end, the striatum is well known to be important for motor learning 
and coordination for which there are several tests available for rodents (reviewed in (Balkaya 
et al., 2013)). 
 
3.4.1 ET-1 stroke causes reproducible ischemic striatal damage 
In order to induce local ischemia in the striatum, either an optic fibre was inserted into the 
striatum for the photothrombotic stroke (in collaboration with Dr. Sara Bragado Alonso in the 
lab) or a mixture of ET-1/L-NAME was injected stereotaxically (Figure 12A). Three days after 
surgery, both methods resulted in a dark stained core of ischemic damage and a penumbra of 
affected tissue surrounding it in a brightfield view (Figure 12B&C). Further histological 
characterization of the ET-1 stroke revealed massive gliosis (GFAP+ cells) around the whole 
striatum whereas an invasion of Iba1+ microglia into the striatum was eminent (Figure 12D). 
DCX+ neuroblasts could be observed outside the SVZ that had migrated into the stroke-
affected area. This effect was not clearly seen after photothrombotic stroke (data not shown) 
as opposed to ET-1. Thus, further histological analysis was focused on the ET-1 stroke only. 
Three weeks after ET-1 stroke, GFAP+ astrocytes had occupied areas in the striatum that were 
absent of Ctip2+ cells and there were still DCX+ migrating neuroblasts indicating the further 
ongoing endogenous stroke response in the brain (Figure 12E). Quantification of these 
migrating neuroblasts relative to the respective stroke volume (at 3 days post stroke (dps) 
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Figure 12: Histology of photothrombotic and ET-1 stroke model in the striatum 
(A) Schematic coronal view of stroke site for either photothrombotic (left) or ET-1 stroke (right). 
Brightfield view of photothrombotic (B, courtesy of Dr. Sara Bragado Alonso) or ET-1 (C) stroke after 
three days. Core and penumbra of ischemic area are indicated. (D) Astrocytes (GFAP+, green), microglia 
(Iba1+, red) and neuroblasts (DCX+, white) 3 dps. (E) Astrocytes (GFAP+, green), striatal neurons 
(Ctip2+, magenta) and neuroblasts (DCX+, white) in the striatum 3 wps. (F) Correlation of stroke volume 
and migrating neuroblasts after 3 dps and 3 wps, respectively. Note the different assessment of stroke 
volume based on Iba1+/GFAP- (3 dps) or Ctip2- (3 wps) areas. (G) Comparison of migrating neuroblasts 
at 3 dps and 3 wps in stroke vs sham injected animals. Letters ‘a-g’ indicate same animals as in (F).	
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identified as Iba1+/GFAP- area and at 3 weeks post stroke (wps) as Ctip2- area) showed a 
positive correlation (R2=0.15 at 3 dps and R2=0.85 at 3 wps) between neuroblast migration 
and stroke volume (Figure 12F). Interestingly, there was no difference of migrating neuroblasts 
in sham vs stroke treated animals 3 dps (1542 ± 656 cells vs 1725 ± 567 cells, p=0.7081, 
student’s t-test with Holm-Sidak correction) but a tendency of elevated migration was seen in 
stroke animals 3 wps (1096 ± 240 cells vs 4348 ± 3171 cells, p=0.1513, student’s t-test with 
Holm-Sidak correction, Figure 12G). 
 
3.4.2 Behavioural assessment of ET-1 and photothrombotic striatum stroke 
As mentioned above, the striatum is an important brain area for motor function. Hence, 
damage caused by ischemic stroke in that area should lead to impairments of motor 
coordination and learning. To address this, animals were first trained before and then tested 
after either photothrombotic or ET-1 stroke on the Catwalk (in collaboration with Dr. Sara 
Bragado Alonso in the lab). This apparatus allows precise gait analysis by recording the mouse 
while walking over a glass platform. Green light shining through the sides of this platform is 
being deflected downwards in a pressure dependent manner where a camera is capturing the 
green light. Using the provided software, the Catwalk system enabled measurement and 
analysis of a plethora of parameters that infer different aspects of gait. However, in both stroke 
models, there were no reproducible differences found in any of the parameters as compared 
to respective sham-treated animals. Here, the “MaxContactMaxIntensity” is shown as a 
representative example for each individual paw after one, two and three weeks after stroke as 
a fold-change compared to the training before (“Baseline”, Figure 13A). This parameter 
describes the maximum intensity of weight the animal puts on the respective paw at the area 
of maximum contact on each step. 
There were two major issues using the Catwalk system ruling it out for future experiments: I) 
the high variability and low reproducibility of trends in some parameters and II) the possibility 
that the caused striatum damage was not big enough to show an effect in such a comparably 
easy task for the mice (walking on a glass platform). Since the ET-1 stroke was histologically 
more promising (Figure 12D-F), all further behaviour tests were only conducted with this 
model. 
ET-1 injections were always performed unilaterally and a past study (Hao et al., 2008) has 
shown that unilateral striatal damage leads to a behavioural effect in the so-called corner test 
(Figure 13B). Here, the mouse is placed into a box with two narrow corners (30˚) and filmed 
from top while moving freely. During its exploratory behaviour, the animal will approach the 
narrow corner and when the whiskers on both sides touch the wall, it will rear back, get up on 
its hind legs and turn around. This turning is performed randomly by healthy animals but is 
supposed to be biased towards the side of striatal damage in stroke animals (i.e. ipsilateral).  
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Figure 13: Behavioural assessment of photothrombotic and ET-1 striatum stroke 
(A) Catwalk gait analysis after stroke. Fold change of MaxContactMaxIntensity compared to baseline 
for each individual paw is shown 1, 2 and 3 wps after photothrombotic (dotted lines) or ET-1 (continuous 
lines) in stroke (red) and sham (black) animals. Data is presented as average ± standard error of the 
mean (SEM). (B) Percentage of ipsilateral turns of mice was assessed in the corner test for stroke (red) 
or sham (black) animals 1 wps as average ± SD. (C) Percentage of time spent at object of stroke (red) 
and sham (black) animals in the novel object recognition task 1 wps is shown as average ± SD. 
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Yet, this effect could not be observed in this experiment (Figure 13B), mainly due to the high 
variability among animals (60.00 ± 25.82 % (sham) vs 73.33 ± 20.66 % (stroke) of ipsilateral 
turns, p=0.4233, unpaired t-test). 
Besides motor coordination, the striatum is also involved in certain memory tasks and a 
commonly used test for striatum-dependent memory is the novel object recognition (NOR) task 
(Figure 13C). In this test, the animal is first habituated in an experimental box with two identical 
objects in two opposite corners and the time is measured that the animals takes exploring 
either of the objects. In following days, a new object replaces one of the two identical ones and 
the exploration time of the new vs the old object is measured. This task can be repeated as 
long as new objects that are different to the previous ones are available. Healthy animals are 
reported to spend more time at new objects due to their curious nature. Mice with impaired 
striatal memory function are supposed to stay at a 50:50 ratio for both objects as it is thought 
that they do not remember the old object. Both the habituation as well as the introduction of 
two new objects were conducted after ET-1 stroke (in collaboration with Dr. Sara Bragado 
Alonso in the lab, Figure 13C). While during habituation, both groups showed no preference 
to either of the two identical objects (50.18 ± 11.86 % vs 46.27 ± 13.56 %, p=0.5110, multiple 
t-test with Holm-Sidak correction), there was a trend of stroke animals spending slightly more 
time at the new object whereas sham animals spent either the same or less time at the new 
object (42.18 ± 18.02 % vs 59.89 ± 18.54 % for new object 1, p=0.0500, multiple t-test with 
Holm-Sidak correction and 38.34 ± 17.98 % vs 56.80 ± 20.55 % for new object 2, p=0.0520, 
multiple t-test with Holm-Sidak correction, Figure 13C). Besides the small magnitude of this 
difference, it was the opposite of the expected effect excluding the NOR from further 
experiments. 
Revisiting the motor coordinative functions of the striatum, a more difficult behavioural task 
compared to the Catwalk was tested. The rotarod consists of a cylinder that the mouse is 
placed on which then starts rotating in an accelerating manner. With higher speed, this task 
becomes more and more difficult until the mouse ultimately cannot walk on the cylinder 
anymore and falls down (Figure 14A). The latency time to fall is the parameter that is measured 
and mice with striatal damage are supposed to fall earlier than control animals. In a first 
experiment, mice were tested on the rotarod 8 days after stroke for two subsequent days per 
week over a course of three weeks with three trials per day (Figure 14B). Both groups showed 
a similar learning curve although stroke animals always performed slightly worse, both during 
learning and after reaching the plateau phase (p=0.1534, two-way ANOVA). 
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Figure 14: Rotarod test of ET-1 striatum stroke model 
(A) Schematic of the rotarod test. (B) Latency to fall (in seconds) from the rotarod of stroke (red) and 
sham (black) animals is shown as average ± SEM 1, 2 and 3 wps for two consecutive days per week. 
(C) Latency to fall (in seconds) of animals during training on the rotarod for three (black) or five (grey) 
trials per day for three or four consecutive days is shown as average ± SEM. (D) Latency to fall (in 
seconds) of animals (stroke (red) or sham (black)) during training and up to 7 wps as average ± SEM is 
shown. (E) Same animals from (D) compared to stroke animals tested every day after stroke (red dotted 
line). Fold change compared to baseline (last day of training) is shown as average ± SEM. 
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A big issue was the variability especially among sham animals which was addressed by first 
training the mice before the surgery. In order to establish a training protocol, two different 
paradigms were tested – three subsequent days of training with three trials per day or four 
subsequent days with five trials per day (Figure 14C). Mice with the latter protocol 
outperformed mice with less training in both learning curve and final performance (p<0.0001, 
two-way ANOVA), hence, this was used for further experiments. After training, mice were 
injected with either ET-1/L-NAME (stroke) or PBS (sham) and subsequently tested on the 
rotarod once per week (again five trials per day) for a total of seven weeks (Figure 14D). After 
an initial drop in performance compared to the last day of training for both groups, shams 
recovered and stayed relatively constant. Stroke animals followed the same pattern but did not 
plateau at the same level as before. However, this was not statistically significant (p=0.5714, 
two-way ANOVA) and also the magnitude of the supposed effect was small (148.67 ± 35.43 s 
vs 122.16 ± 44.51 s at 7 wps). In a separate experiment, the short-term effect of stroke was 
assessed by testing the animals every day on the rotarod in the first week post stroke, followed 
by the standard weekly testing. When comparing the short-term group to the long-term 
experiment by expressing the values as fold change compared to baseline, the short-term 
stroke group seemed to follow the same trend as the long-term stroke group (Figure 14E). 
Interestingly, there was a big drop in rotarod performance at day 3 post stroke but mice 
recovered within the remaining days of the first week. Once switched to the weekly rotarod 
testing, they showed the same initial downwards trend as the long-term tested stroke mice that 
both groups never recovered from. 
Further tests aimed at increasing the potential difference between stroke and sham on the 
rotarod by various means. A more difficult training protocol (two days of training as before 
followed by three days of faster acceleration which was maintained for testing after stroke) did 
not show any difference between sham and stroke (data not shown). Furthermore, both 
bilateral striatal strokes (instead of unilateral as before) or double injections unilaterally did not 
even show the previously observed trend of a difference (data not shown). It was therefore 
concluded that the first long-term experiment (Figure 14D) was not reproducible and thus not 
biologically relevant. 
To summarize, the here used behavioural tests did not reveal a reproducible phenotype after 
ET-1 striatum stroke although further experiments such as a complex running wheel might 
allow the detection of subtle differences cause by the small ischemic damage. Subsequently, 
a combination of both major parts in this thesis – rAAV-4D injection and ET-1 striatum stroke 
– was only done for histological, but not for behavioural analysis. 
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3.5 4D increases the number of migrating neuroblasts and survival after stroke 
Initially, the aim of this project was combining a clinically applicable 4D-mediated expansion of 
the NSC pool with a neurodegenerative disease model on both histological and behavioural 
level to demonstrate the therapeutical potential of 4D. Due to the lack of a suitable behavioural 
test for the established ET-1 striatum stroke, the focus was set on histology only. 
To this end, mice received in a single surgery an ET-1/L-NAME injection into the striatum in 
one hemisphere and rAAV-4D or -GFP into the contralateral ventricle (Figure 15A). 
As previously seen in the ET-1 stroke experiments (Figure 12D-G), the striatal ischemic 
damage triggered an endogenous response of migrating neuroblasts towards the striatum. 
Thus, DCX+ migrating neuroblasts were quantified after stroke and rAAV-4D or -GFP injection 
3 wps and 6 wps (Figure 15C). The number of neuroblasts was increased in 4D animals 
compared to GFP at 3 wps from 3141 ± 2151 cells to 9224 ± 5248 cells (no t-test possible 
because of n=2 for GFP animals) and at 6 wps from 1236 ± 603 cells to 3536 ± 2259 cells 
(p=0.1637, multiple t-test with Holm-Sidak correction). Normalisation of those numbers to the 
respective stroke volume did not influence this result (data not shown). Interestingly, the 
number of DCX+ cells after 3 weeks in GFP injected animals was very similar to those of only 
stroke injected animals (3141 ± 2151 cells vs 4348 ± 3171 cells, see also Figure 12F). 
In order to assess neuronal survival, newborn cells were birthdated with BrdU in the third week 
after injection (Figure 15B) because of the previously characterised 4D effect under 
physiological conditions in this time frame (Figure 8F & Figure 9C). Quantification of newborn 
neurons in the striatum (BrdU+NeuN+) normalised to all birthdated cells (BrdU+) did not show 
any difference in GFP vs 4D animals at 6 wps (19.22 ± 3.65 % vs 19.43 ± 3.79 %, Figure 15D) 
but the absolute number of BrdU+NeuN+ cells in the striatum normalised per volume was 
slightly increased in 4D injected animals (231 ± 122 cells per mm3 vs 372 ± 143 cells per mm3, 
p=0.2684, unpaired t-test). A similar experiment was conducted in the 4D mouse line (Bragado 
Alonso et al., 2019) in collaboration with Dr. Sara Bragado Alonso in our lab (data not shown). 
Here, BrdU was given in parallel to the 4D induction one day post stroke for four days. Six 
weeks later, there was a significant increase in BrdU+NeuN+ cells per volume and similar to 
the rAAV results, the percentage of newborn neurons among all birthdated cells was 
unchanged compared to control animals. This data further corroborated the findings presented 
here. 
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Figure 15: Assessment of rAAV-4D increased neurogenesis after ET-1 striatum stroke 
(A) Schematic coronal view of rAAV ventricle and contralateral ET-1 striatum injection. (B) Timeline of 
mouse treatments in this experiment. ‘X’ indicates time points of sacrifices, BrdU i.p. injections were 
given twice per day. (C) DCX+ cells in the striatum were quantified 3 and 6 wps for GFP and 4D injected 
animals and compared to stroke only animals at 3 wps. (D) Neuronal survival (NeuN+BrdU+) was 
quantified 6 wps either normalised to all BrdU+ cells or per striatal volume for GFP and 4D injected 
animals. Average ± SD is shown in all graphs. (E) DCX+ (white) and YFP+ (yellow) cells of Confetti mice 
are shown 6 wps for both Cre or Cre4D injected animals. 
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In line with the previous rAAV injections without stroke (Figure 9), no GFP+ cell was observed 
outside of the SVZ also in stroke conditions. In order to better investigate the progeny of rAAV-
transduced cells that had migrated to the striatum, the same lineage-tracing approach as 
before was applied using Confetti mice and rAAV-Cre4D or -Cre. In this experiment, only few 
YFP+ cells outside the SVZ were observed 6 weeks post stroke (Figure 15E), some of which 
were displaying more neuronal or astrocytic morphology. Moreover, there was no DCX+/YFP+ 
cell outside the SVZ identified, although there were still many migrating DCX+ neuroblasts 
detected. 
In summary, it is still unclear as to how many of the transduced cells actually contributed 
towards migrating neuroblasts and further functional characterisations are still pending. 
Nevertheless, this work provides evidence for a rAAV-4D increased number of migrating 
neuroblasts and a trend of increased neuronal survival after striatal ischemic stroke. Thus, 
rAAV-mediated 4D overexpression in SVZ NSCs is promising for the therapeutic use of stroke 
and potentially other neurodegenerative diseases. 
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4 .  D I S C U S S I O N  
The aims of this thesis were (I) establishing a rAAV-4D overexpression system in NSCs, (II) 
characterising an ischemic stroke model on histological and behavioural level and (III) testing 
the rAAV-4D overexpression of NSCs in the stroke model thus providing evidence for the 
regenerative potential of NSC pool expansion in neurodegenerative diseases. The successful 
rAAV-4D-mediated increase in SVZ neurogenesis and establishment of a histologically 
reproducible stroke model enabled the characterisation of the 4D effect after stroke. An 
increased number of migrating neuroblasts and neuronal survival demonstrated the 
therapeutic potential of 4D which will be corroborated by future electrophysiological and 
behavioural investigations. 
 
4.1 rAAVr3.45 transduces NSCs in vivo 
Recombinant adeno-associated viruses have been used for gene delivery and clinical 
applications for many years and along with it, different purification methods had been 
developed (Flotte et al., 1996). Previously, a protocol including long ultracentrifugations and 
the cytotoxic CsCl3 had been used for in vivo applications (Flotte et al., 1992). Later on, 
researchers had established a shorter protocol involving the biologically inert iodixanol 
(Zolotukhin et al., 1999). Affinity-based chromatography purification protocols had also been 
used in the past and are now being designed for multiple serotypes. Yet, these are still more 
cumbersome than the iodixanol protocol and have to be evaluated and adapted for each 
serotype (Nass et al., 2018). Importantly, there are reports that the transduction efficiency of 
the same rAAV serotype in vivo, purified with one or the other method, can lead to different 
apparent tropisms of the virus (Klein et al., 2008). Thus, when testing a certain serotype for its 
transduction efficiency for a specific cell type, not only the promoter and the serotype itself 
have to be taken into consideration but also the purification method. For this work, the iodixanol 
method was chosen since it allows a serotype-independent purification of high titer and high 
purity rAAVs. 
In the last decade, more and more strategies have been developed to increase the amount of 
different available serotypes. These involved usually starting off with one of the naturally 
occurring serotypes and introducing mutations in the Cap gene coding for the capsid protein 
by various means. Combined with different screening methods, this led to a growing amount 
of so-called engineered serotypes targeting specific cell types in vivo (reviewed in (Kotterman 
and Schaffer, 2014). 
Here, an iodixanol purification protocol was adapted from Strobel et al. and established for 
several naturally occurring serotypes and also for the NSC-engineered serotype r3.45 resulting 
in high purity rAAVs (Kotterman et al., 2015b; Strobel et al., 2015). The qPCR titration only 
measured the amount of packaged rAAV particles (vs an unknown amount of non-packaged 
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particles) but is predominantly used in the field since rAAVs are reportedly very inefficient in in 
vitro transduction of various cell lines (Ellis et al., 2013) and due to the ability to compare titers 
of different serotypes. Electron microscopy would enable the quantification of unpackaged 
rAAV particles and the iodixanol method has been shown to result in 20 % of empty purified 
rAAV particles (Strobel et al., 2015). 
As mentioned above, not only the serotype, but also the promoter can influence the apparent 
transduction efficiency of a cell type. This effect was seen when injecting serotype 9 in the 
hippocampus with either a CMV-GFP or UbGFP construct (Figure 11). Furthermore, the 
efficiency of engineered serotypes vs natural serotypes was clearly demonstrated as r3.45 
was able to transduce more granule cells than serotype 9 and it was the only one to transduce 
SVZ NSCs. As r3.45 was a promising candidate for both neurogenic zones but the SVZ NSCs 
and their progeny have more potential applications for a bigger variety of neurodegenerative 
diseases including stroke, the characterization of the 4D-mediated effect was continued only 
in the SVZ NSCs for rAAVr3.45. 
 
4.2 rAAV-4D increases SVZ NSC proliferation and OB neurogenesis 
Injection of rAAVr3.45 into the lateral ventricle resulted in widespread transduction of cells in 
the SVZ, interestingly in both hemispheres although injection was only done in one (Figure 8). 
Comparing the NSC transduction efficiency of the used rAAVs here (~2 %) to other attempts 
in the literature is difficult based on the different criteria that had been applied. Using another 
engineered rAAV serotype, the Schaffer lab claimed to transduce 60 % of SVZ NSCs (Ojala 
et al., 2018). In this study, cells were labelled with BrdU three days before rAAV injection into 
the ventricle and NSCs were subsequently regarded as GFAP+/BrdU+/DCX-. GFAP is also 
expressed in astrocytes and known as an important marker for proliferating neuronal 
progenitors but not necessarily NSCs (Garcia et al., 2004). Thus, the reported number of 60 % 
transduced NSCs is most likely an overestimation as compared to Nestin+/S100b- markers in 
this work. Lentiviruses and retroviruses have also been used in the past but typically by 
injection into the SVZ directly (as opposed to the ventricle) thereby leading to only a local 
transduction of cells without proper quantification of transduced NSCs (Carleton et al., 2003; 
Consiglio et al., 2004). 
When investigating the effect of 4D on NSC proliferation, all EdU-labelled cycling cells of the 
last two days before sacrifice were used as an approximation. Of note, also newborn and 
cycling progenitors that have not yet migrated from the SVZ towards the RMS were included 
in this quantification. As expected from previous results in the SVZ using the 4D transgenic 
mouse line in our lab (Bragado Alonso et al., 2019) or in the SGZ using lentiviruses (Artegiani 
et al., 2011), an increase in proliferation of 4D vs GFP injected animals was observed after 
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3 weeks (Figure 8) although there was no concomitant increase in differentiating neuroblasts 
(DCX+, Figure 9). 
One possible explanation to this apparent discrepancy between increased cell proliferation 
and unchanged number of neuroblasts is that the produced excess of DCX+ cells had migrated 
and thus was not measured in the SVZ. Moreover, rAAVs do not integrate into the genome 
and are thereby diluted out over cell divisions. It is therefore expected that cells lose both the 
rAAV genome and the expressed GFP (and 4D) proteins over several cell divisions. This has 
been reported also in another study transducing SVZ NSCs (Ojala et al., 2018). Since 4D is 
even promoting cell divisions, this effect is expected to be stronger in 4D expressing cells. 
Following this logic, observing equal values of DCX+GFP+ cells in both 4D and GFP injected 
animals is still in line with the expected 4D effect. 
Similarly, the absence of GFP+ cells outside the SVZ can be explained. Migrating neuroblasts 
in the RMS have already undergone several cell divisions and keep on dividing until they finally 
reach the OB (Ponti et al., 2013). It is therefore not surprising to observe no GFP+ cell in the 
RMS or the OB. Importantly, the number of four-week-old BrdU-birthdated newborn neurons 
was increased a total of seven weeks after rAAV injection (Figure 9C). Interestingly, the 
magnitude of the effect (~40 % increase in 4D vs GFP) is comparable to the 4D transgenic 
mouse line (Bragado Alonso et al., 2019) although rAAVs only transduced a small fraction of 
SVZ NSCs (Figure 8E) as compared to ~50 % of NSCs in the mouse line. This counterintuitive 
observation could be explained by the different expression time of 4D. 
In the transgenic mouse, 4D was only induced for four days whereas rAAV-mediated 4D 
overexpression was never actively stopped besides the dilution of the viral genome over cell 
divisions. Thus, it could be assumed that a short time of 4D overexpression in the majority of 
NSCs resulted in the same neurogenic output as did a longer period of 4D activity in less 
NSCs. Previous studies in our lab have shown that 4D does not influence the balance of 
quiescent vs active cycling NSCs (Bragado Alonso et al., 2019) and that cyclinD1 is degraded 
in non-G1 cells (Lange et al., 2009). If 4D is overexpressed in many (or all) NSCs, this will not 
change the fact that only a subpopulation of them is susceptible to its effect over the time 
course of four days. Whereas in case of the rAAVs, a smaller proportion of NSCs is 
overexpressing 4D, but this should not be diluted in a non-dividing quiescent NSC. 
Consequently, there is the potential of a sustained increased level of proliferation over a longer 
time period because 4D will eventually trigger its effect in any transduced NSC once it switches 
from quiescence to active, ultimately leading to the same accumulated magnitude of increased 
neurogenesis after several weeks. 
Addressing the issue of absent GFP+ cells outside the SVZ, it can be excluded that the 
transduced proliferating cells died because of the increased number of BrdU+ cells observed 
in the OB of rAAV-4D animals and based on the Cre-lineage tracing with the Confetti mouse. 
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This experiment also proved migration of the transduced cells via the RMS to the OB further 
corroborating the dilution-over-cell-divisions hypothesis. A previous study had obtained similar 
results for a different rAAV serotype using another reporter mouse line (Ojala et al., 2018). Yet, 
when this mouse line was tested in our lab, it was deemed not ideal, since there were a lot of 
RFP+ cells present especially in the OB already before Cre recombination (data not shown). 
In contrast, in the Confetti mouse line, there was no fluorescent protein detected without Cre 
expression as expected (data not shown). Thus, the YFP+ cells observed in the SVZ, RMS 
and OB can be considered as actual recombination events due to the rAAV-delivered Cre 
(Figure 10C-E). 
In conclusion, the establishment of the rAAV-4D system in mice was successful in the key 
points of (I) identification of a serotype that transduces NSCs in vivo, (II) increasing proliferation 
of SVZ NSCs, ultimately leading to (III) a higher number of newborn neurons in the olfactory 
bulb. All this was achieved under circumstances that could be applied to larger animal models 
and eventually humans since rAAVs are already being used in clinical trials (Bailey et al., 2018; 
Taghian et al., 2019). 
The only concern for clinical applications could be the so far uncontrollable time of 4D 
expression after transduction since here, a constitutive promoter has been used. However, it 
has been shown that over cell divisions, the rAAV-driven overexpression is lost and combined 
with the fact that our lab has demonstrated before that 4D does not have any observable effect 
on post-mitotic (Artegiani et al., 2011) or quiescent (Bragado Alonso et al., 2019) cells and that 
cyclinD1 is degraded in non-G1 cells (Lange et al., 2009), this is not necessarily a major issue. 
Nevertheless, a Tet-inducible 4D expression system could be used instead of a constitutive 
promoter. In this case, rtTA expression would be driven by a constitutive promoter and 4D 
under the control of a TetOn promoter which is only active when doxycyclin-activated rtTA 
binds to it. Thus, doxycyclin would have to be administered to the animal or patient. Yet, there 
are reports of an immune response in larger animal models to the TetOn system (Le Guiner et 
al., 2007), questioning its applicability for clinical trials. 
 
4.3 Establishment of an inducible striatum stroke model 
The aim of this thesis was to assess whether 4D overexpression in NSCs could be used as a 
treatment for stroke. Regarding the stroke model alternatives, MCAo/CCAo were not 
considered because of the large damage this model typically induces and due to the low 
controllability of the stroke location. The other two primarily used models in the field – 
photothrombotic and ET-1 stroke – were both initially assessed regarding their ability to induce 
a reproducible stroke in the striatum.  
Targeting the striatum for the stroke had several reasons. On the one hand, the SVZ NSCs 
are located next to the striatum. Thus, any damage-induced migration would be much more 
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likely to happen in an area that is close to the origin of these migrating cells. On the other hand, 
the aim was to induce a stroke in a brain area that would enable the detection of this damage 
on a behavioural level since this is at least as clinically relevant as histological analyses. The 
striatum is known for its importance in motor and cognitive functions (Wise, 2004) such as 
working memory (Dalley et al., 2004) and motivational and goal-oriented learning (Graybiel, 
2008). Consequently, this would enable the investigation of several behavioural aspects and 
ideally a detailed description and readout of the effects caused by the damage. 
 
4.3.1 ET-1 stroke causes reproducible ischemic striatal damage 
Histologically, both tested stroke models generated injuries that were visible three days post 
stroke in a brightfield view but migrating neuroblasts from the SVZ towards the injury site were 
only observed in the case of ET-1. This migration was stroke size dependent as reported also 
in a ET-1 striatum rat model (Lima et al., 2016). Interestingly, the stroke volume assessed at 
three days and three weeks post stroke with different markers was differing by one order of 
magnitude indicating that even though a major area of the striatum seemed to show an initial 
response to the ET-1 injection, not nearly as many neurons were affected by it long-term. 
Stainings for astrocytes and microglia at these time points allowed to draw the following model 
of the timeline for the physiological ET-1 stroke response reaction which had also been 
observed in other stroke models in rats (Abeysinghe et al., 2014; Rewell et al., 2017): 
Within the first few days, microglia invade the ischemic area, possibly to phagocytose dying 
cells or cell debris. Concomitantly, astrocytes are activated and start surrounding the stroke 
area. However, maybe for signalling reasons of other cell types, they do not invade yet. This 
happens some time afterwards, possibly once microglia have finished clearing out dead cells 
and the astrocytes occupy the area of absent neurons which is called glial scarring. The roles 
of both microglia and astrocytes in ischemic stroke are still not fully understood but both 
negative impacts such as glial scarring or inflammatory signals and positive functions like 
neuroprotection, synaptogenesis or angiogenesis for the recovery have been reported 
(Becerra-Calixto and Cardona-Gomez, 2017; Qin et al., 2019; Sun et al., 2019). 
 
4.3.2 Behavioural assessment of ET-1 and photothrombotic striatum stroke 
On the behavioural level, several tasks were used to assess the functional damage caused by 
ET-1 striatum stroke. Neither motor functional tests (easy tasks like the Catwalk or more 
difficult like the rotarod), nor sensorimotor function (corner test) or a striatum-dependent 
memory test (NOR) showed any reproducible effect on stroke vs sham animals. 
The Catwalk data (Figure 13A) never revealed any major parameter changes for both stroke 
models and more subtle changes of less than 10 % were not reproducibly observable due to 
the high variability of this test. Efforts to improve the training protocol previously or post-hoc 
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data analysis such as normalisation to weight or speed of the animal and even to the swing 
speed of each individual paw did not alleviate this problem. The Catwalk gait analysis has been 
used in other models of spinal cord injuries (Hamers et al., 2006) and neurodegenerative 
diseases such as MS (Herold et al., 2016), HD or PD (Timotius et al., 2019). However, these 
models all impacted the entire animal more severely, supporting the hypothesis that the mild 
stroke induced here was not enough to show an impairment on the Catwalk. 
The corner test (Figure 13B) was conducted once without recording pre-treatment values. 
Thus, major conclusions cannot be drawn from this single time experiment. The relatively low 
resolution of 10 % increments could be decreased by recording more turns per animal. Yet, 
this would still not change the high variability among animals. Moreover, since a rAAV-4D 
treatment would be probably very difficult to detect with this behaviour test after stroke, the 
corner test was not considered for the future, especially taking into account another study that 
demonstrated no difference after ET-1 cortical stroke in this test (Tennant and Jones, 2009). 
The NOR task did not show the expected and reported behaviour of the sham mice (Lueptow, 
2017) as in spending more time at new objects (Figure 13C). Therefore, the results of the 
stroke animals cannot be interpreted properly. It cannot be excluded that the new objects were 
either not different enough from the old one or that they were repelling to the animals for some 
reason. Both cases could explain the lack of interest or aversion of sham animals regarding 
the new objects. Thus, a new set of objects first would have to be tested and established for 
control animals before any treated mice could be analysed with this behavioural task. 
Lastly, mice were assessed on the rotarod for motor coordination (Figure 14). While an initial 
test without pre-training showed a promising trend, it could ultimately not be reproduced 
despite many efforts of improving both the training protocol as well as analysing the behaviour 
after stroke. Remarkably, both the massive glial response observed after three days and the 
detected neuronal loss after three weeks seemed to be concomitant with a respective drop in 
rotarod performance of stroke animals. Yet, the lack of intermediate histological time points 
does not allow to draw major conclusions as to why mice seemed to recover from this reduced 
performance on the rotarod three days and three weeks after stroke, respectively. This could 
possibly be related to the cellular processes happening in the brain which is still to be revealed. 
Considering the histologically detected damage and cellular responses, the question is being 
raised as to why no behavioural effect could be detected in any of the used tests. Of note, 
when mice were waking up from the surgery, seizures combined with ipsilateral circling was 
observed in many stroke animals within the first hour but in none of the shams, indicating an 
immediate response to the ET-1 injection. Thus, it is very unlikely that the caused damage had 
no effect on the brain at all. 
Admittedly, it is possible that either the damage was not big enough or that the used tests were 
not appropriate for the striatal damage caused. Concerning the former, injections of double 
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volume of ET-1 or two single injections in different locations of the striatum (but the same 
hemisphere) did also not result in behavioural deficits in the rotarod (data not shown). 
Regarding the latter, it cannot be excluded that other tests could have revealed an effect after 
striatal stroke. Especially when regarding the olfactometry test for 4D-increased SVZ 
neurogenesis (Bragado Alonso et al., 2019), a behavioural difference could only be seen when 
the test was very challenging for the animals. Thus, finding a motor behavioural test that 
challenges the mice more could reveal subtle differences in animals with small striatal damage. 
For example, the complex running wheel could be used in order to detect whether striatal 
stroke could cause a deficit in motor coordination. 
 
4.4 4D increases the number of migrating neuroblasts and neuronal survival 
after stroke 
In stroke and other neurodegenerative diseases, neurons are lost either region- or subtype-
specifically or without any obvious preference. Either way, the ultimate goal of regenerative 
therapies is replacing those lost neurons. Here, I focused on harnessing the endogenous NSC 
pool and on using rAAV-4D overexpression to increase their proliferative capacity for this 
purpose in the context of striatal stroke. 
Three important criteria had to be fulfilled in order to show therapeutic potential: (I) (increased 
number of) migrating neuroblasts towards the site of injury, (II) neuronal survival and (III) 
functional integration into the existing network of remaining neurons. 
It had already been reported previously that SVZ NSC progeny migrates towards the site of 
injury after stroke (Ohab et al., 2006; Marques et al., 2019) which was confirmed also in this 
work. Furthermore, a trend of higher numbers of migrating neuroblasts and of increased 
neuronal survival in 4D animals indicated the potential regenerative use of rAAV-4D. 
Expectedly, the proportion of newborn neurons among all birthdated cells was not changed in 
4D- or GFP-injected animals since there is no evidence that 4D influences the fate of NSCs 
(Lange et al., 2009; Artegiani et al., 2011; Nonaka-Kinoshita et al., 2013; Bragado Alonso et 
al., 2019; Berdugo-Vega et al., 2020). A similar histological analysis after stroke had also been 
conducted in our lab using the 4D transgenic mouse line resulting in bigger effects as 
compared to rAAV-4D further corroborating these findings. 
For better analysis of integration of surviving neurons in the striatum originating from SVZ 
NSCs, a Cre-lineage tracing approach was used and only very few YFP+ cells were found in 
the striatum and none of them were DCX+ (Figure 15). This is in contrast to the discussed data 
using the BrdU-birthdating approach and one explanation could be the heterogeneity of SVZ 
NSCs (Young et al., 2007; Obernier and Alvarez-Buylla, 2019). rAAVs possibly transduce only 
a certain subpopulation of NSCs that can contribute to migrating neuroblasts towards the OB 
(as shown in the previous lineage tracing experiment, Figure 10) but maybe not to migrating 
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neuroblasts towards the injury site. In that case, the increased number of migrating neuroblasts 
and neuronal survival in 4D animals could be explained by a regulatory compensation 
mechanism. If rAAV-4D transduced NSCs managed to maintain the normal levels of OB 
neurogenesis, other subpopulations of SVZ NSC could have contributed more to the 
regenerative purposes. 
The fate of the observed migrating neuroblasts and newborn neurons has not yet been further 
investigated in this work. Previously, several studies have demonstrated that after ischemic 
striatal damage, neuroblasts from the SVZ migrate towards the site of injury (Zhang et al., 
2007) and differentiate to subtypes that naturally are present in the striatum such as  
DARP-32+ (Arvidsson et al., 2002; Parent et al., 2002), GABAergic and cholinergic neurons 
(Hou et al., 2008) or parvalbumin and neuropeptide Y expressing interneurons (Collin et al., 
2005). Of note, these studies were done in rats with the more commonly used MCAo stroke 
model. Yet, in a recent review, it has been pointed out that it is still not clear whether there is 
local neurogenesis in the striatum after injury, that results might be species-dependent and 
that conflicting reports might be due to the different techniques used in those studies both for 
investigating the origin of newborn neurons and the caused striatal damage (Nemirovich-
Danchenko and Khodanovich, 2019). Regarding translational applicability of findings in this 
and the work of other groups on animal models of stroke, there are a few studies providing 
evidence for increased neurogenesis in human brains after stroke (Jin et al., 2006; Minger et 
al., 2007). 
Concluding, I presented first data that rAAV-4D overexpression after ET-1 stroke potentially 
increases both the number of migrating neuroblasts and their survival. Their functional 
characterization is still pending and future efforts should be made towards identifying a suitable 
behavioural test to also demonstrate an improvement of the animal beyond cellular 
regeneration. 
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4.5 Future perspectives 
The work presented in this thesis provided first evidence that a 4D-mediated increase of SVZ 
NSCs can be a potential treatment for neurodegenerative diseases and for stroke in particular. 
Moreover, rAAVs (and the 4D overexpression) do not have to be restricted to NSCs. In fact, 
collaborative research with other groups and other projects in our lab have suggested that 4D 
is exerting its effect on any stem cell type, from human hematopoietic stem cells in a mouse 
model (Mende et al., 2015) to oligodendrocyte progenitors in adult mice (unpublished work by 
Dr. Max Schulze-Steikow). Consequently, identification of a suitable rAAV serotype for the 
stem cell of choice could quickly lead to a ready-to-use system to expand this stem cell pool 
and to test it for regenerative purposes. Ongoing research on engineering rAAV serotypes 
towards specific cell types will expand this tool box and facilitate specific transduction of cell 
types for gene therapy (Kotterman and Schaffer, 2014). 
Proof of an integration of the 4D-produced newborn neurons and investigation of their 
electrophysiological properties additional to a behavioural readout in the future would further 
corroborate the findings of this thesis. The research on this stroke disease model could then 
be expanded to other neurodegenerative disease models increasing the therapeutic potential 
of rAAV-4D treatments. 
.  
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Summary 
Adult neurogenesis in mammals is restricted to two areas of the brain, the hippocampal 
subgranular zone (SGZ) and the subventricular zone (SVZ) lining the ventricle walls. Previous 
work in our lab has shown that overexpression of the cell cycle regulators Cdk4/Ccnd1 (4D) in 
SGZ or SVZ neural stem cells (NSCs) shortens their G1 thereby resulting in an increased rate 
of proliferation. This led to a higher number of newborn neurons improving the performances 
of mice in hippocampus-dependent memory or odour discrimination tasks, respectively. 
However, the 4D overexpression was so far achieved using integrating lentiviruses (SGZ) or 
transgenic mice (SVZ) limiting this approach from potential clinical applications such as stroke 
and other neurodegenerative diseases. In my thesis, I set out to develop a 4D overexpression 
system that is clinically applicable and to test this in a mouse model of stroke. To this end, a 
recombinant adeno-associated virus (rAAV) serotype was for the first time identified that 
enabled the transduction of both SGZ and SVZ NSCs. In the SVZ, 4D overexpression resulted 
in increased NSC proliferation and neurogenesis providing a proof of principle for the rAAV-
4D system. Additionally, a photothrombotic and an endothelin-1 (ET-1) striatum stroke model 
were established for both histological and behavioural analysis. In the ET-1 model, SVZ-
derived neuroblast migration towards the site of injury was observed. Histological analysis of 
rAAV-mediated 4D overexpression after ET-1 stroke demonstrated an increased number of 
migrating neuroblasts and neuronal survival in the striatum. Together with future cellular 
characterizations and behavioural tests, this work provides the basis for potential 4D 
applications not only for stroke but also for other neurodegenerative diseases. In a bigger 
picture, identification of rAAV serotypes that transduce other stem and progenitor cells could 
even further expand the toolbox of rAAV-4D treatments for clinical applications of different 
areas of regenerative medicine. 
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Zusammenfassung 
Adulte Neurogenese in Säugetieren ist eingeschränkt auf zwei Gehirnbereiche, der 
subgranulären Zone (SGZ) des Hippocampus und der subventrikulären Zone (SVZ) um die 
Ventrikelwände herum. Vorhergehende Arbeiten in unserem Labor haben gezeigt, dass 
Überexpression der Zellzyklusregulatoren Cdk4/Ccnd1 (4D) in neuralen Stammzellen (NSZ) 
der SGZ oder SVZ ihre G1 Phase verkürzt und dadurch zu einer erhöhten Proliferationsrate 
führt. Dies hatte eine höhere Anzahl an neugeborenen Neuronen zur Folge, welche die 
Performance von Mäusen in Hippocampus-abhängigen Gedächtnis- bzw. in Geruch-
unterscheidungstests verbessert hat. Allerdings wurde die 4D Überexpression bislang durch 
das Benutzen von entweder integrierenden Lentiviren (SGZ) oder transgenen Mäusen (SVZ) 
durchgeführt, was diese Vorgehensweise einschränkt hinsichtlich potenzieller klinischer 
Anwendungen wie Schlaganfall oder neurodegenerativen Erkrankungen. In meiner Thesis 
habe ich ein 4D Überexpressionssystem entwickelt, was klinisch anwendbar ist und dies in 
einem Mausmodell von Schlaganfall getestet. Zu diesem Zweck wurde zum ersten Mal ein 
rekombinanter Adeno-assoziierter Virus (rAAV) Serotyp identifiziert, der die Transduktion von 
sowohl SGZ als auch SVZ NSZs ermöglichte. In der SVZ resultierte die 4D Überexpression in 
einer erhöhten NSZ Proliferation und Neurogenese, was einen grundlegenden Beweis für das 
rAAV-4D System lieferte. Zusätzlich wurden ein photothrombotisches und ein Endothelin-1 
(ET-1) Striatum Schlaganfallmodell sowohl für histologische als auch Verhaltens-
untersuchungen etabliert. Im ET-1 Modell wurde Migration von Neuroblasten zum Bereich der 
Schädigung hin beobachtet, die von der SVZ stammten. Histologische Analysen der rAAV-4D 
Überexpression nach ET-1 Schlaganfall wiesen eine erhöhte Anzahl an migrierenden 
Neuroblasten und Überleben der Neuronen auf. Zusammen mit zukünftigen zellulären 
Charakterisierungen und Verhaltenstests liefert diese Arbeit die Basis für potenzielle 4D 
Anwendungen nicht nur für Schlaganfall, sondern auch für andere neurodegenerative 
Erkrankungen. Perspektivisch könnte die Identifizierung von rAAV Serotypen, die andere 
Stamm- oder Vorläuferzellen transduzieren, weiter die Toolbox von rAAV-4D Behandlungs-
möglichkeiten für klinische Anwendungen anderer Bereiche der regenerativen Medizin 
erweitern. 
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